Oncology Drugs Market By Indication (Breast Cancer, Prostate Cancer, Basal Cell Cancer, Skin Cancer (Non-Melanoma), Colorectal Cancer, Lung Cancer, Renal Cancer, Bladder Cancer, Lymphoma and Others), By Treatment (Drug Therapies (Antimetabolites, Antitumor Antibiotics, Asparagine-Specific Enzymes, Bisphosphonates and Biosimilars, DNA-Damaging Agents (Antineoplastics) and Alkylating Agents, Inhibitors(DNA-Repair Enzyme Inhibitors, Histone Deacetylase Inhibitors, Janus-Associated Kinase (JAK) Inhibitors, Proteasome Inhibitors, Tyrosine Kinase Inhibitors, PD-1 and PD-L1 Inhibitors and Others)), Surgery (Open Surgery and Minimally Invasive Surgery), Radiation Therapy, Chemotherapy, Immunotherapy (Chimeric Antigen Receptor (CAR) T-Cell Therapy, Cytokine Treatment, Donor Lymphocyte Infusion, Monoclonal Antibody Treatment and Others), Targeted Therapy, Hormone Therapy, Stem Cell Transplant (Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Reduced-Intensity Allogeneic Stem Cell Transplantation, Graft-Versus-Host Disease), Precision Medicine and Others), By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027

Report ID :AMI-273 | Category : Healthcare | Published Date : September, 2019 | Pages : 600 | Format :PDF
Buy Now!

Industry Trends

Global oncology drugs market was estimated to be US$ 119 billion in 2018 is expected to reach US$ 350.01 billion by 2027, growing at an estimated CAGR of 12.7% over the forecast period. The geriatric population in the United States possess certain behaviors such as smoking, not being physically active and eating an unhealthy diet. Rising number of the same has aided the overall cancer drugs market. Development of new anti-cancer molecules coupled with favorable government initiatives has assisted the overall growth of the industry.

Amongst the drug type, the usage of immune-oncology PD-1 and PD-L1 inhibitors have recently witnessed a rapid growth owing to its remarkable clinical profile and their approval for various cancer types. The same is having a larger penetration as a new treatment option amongst patient suffering from metastatic melanoma. There has been an increased focus on personalized medicine that is in turn, leading to patient segmentation based biomarker status. There were 14 New Active Substance cancer therapeutics that was launched in 2017. They solely catered to targeted therapies. Out of which, 11 therapies got their approval from FDA. However, adverse effects associated with cancer drugs and high cost of the cancer drugs are some of factors that is anticipated to critically impact the global oncology drugs market.

Breast cancer has the highest share in 2018 and is expected to continue the same trend over the next eight years. One of the product named Neulasta, offered by Amgen, Inc. is being used by women with stage 4 breast cancer. The drug reported to reduce the risk of febrile neutropenia during chemotherapy by 97% compared to a placebo. It has been duly reported that in most cases adjuvant treat .i.e., chemotherapy with combination of drugs is considered a more favorable option compared to single combination. Some of the adjuvant drugs that are used are anthracyclines, taxanes, 5-fluorouracil, cyclophosphamide and carboplatin are the most demanded drug of Oncology Drugs Market.

In terms of revenue, stem cell transplants is expected to witness a considerable CAGR over the forecast period. This procedure restores blood-forming stem cells in people who have had their destroyed in chemotherapy or radiation therapy to treat cancers. There are two main types of stem cell transplants which are autologous and allogeneic. This treatment primarily help people who suffer from lymphoma and leukemia. They may be also used for multiple myeloma and neuroblastoma.

North America region held more than 45% of the overall Oncology Drugs Market and is anticipated to continue the same trend over the forecast period. In terms of penetration, the European Union hold the second position. The highest number of agents which are newly launched cancer drugs from 2011 to 2015 period are available in the United States and Germany. The reimbursement process differs by geography and the reimbursement ranges from 100% to 61% across countries. Also, owing to advances in cancer treatment, the mortality rates has steadily declined across the major developed countries in the recent past. This decline was the highest in France, followed by the United States and Japan. The improvement in the mortality rates is also due to factors such as early diagnosis, rise in screening services along with the introduction of new drugs (agents) that incorporates the diverse action mechanism.

A drug named Avelumab, approved in March 2017 is introduced for metastatic Merkel cell carcinoma which is a rare aggressive skin cancer type. Other therapies such as MEK inhibitors, BRAF inhibitors and anti-CTLA4 agents for melanoma application have been launched in the recent past.

Thus, the introduction of new drugs along with therapies associated with cancer can diminish the prevalence of the disease in various regions. Also, preventive measures are being increasingly taken by people wherein, they adopt healthy lifestyle and diet. Such factors are expected to reduce the incidence of these diseases in future years.

Global, Oncology Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2027

Competitive Landscape

The report provides both, qualitative and quantitative research of Oncology Drugs Market, as well as provides comprehensive insights and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, specification, pricing, and gross margin.

Some of the players operating in the oncology drugs market are F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Merck & Co., Inc.,CELGENE CORPORATION and Polaris Pharmaceuticals amongst others

  • By Indication
    • Breast Cancer
    • Prostate Cancer
    • Basal Cell Cancer
    • Skin Cancer (Non-Melanoma)
    • Colorectal cancer
    • Lung Cancer
    • Renal Cancer
    • Bladder Cancer
    • Lymphoma
    • Others
  • By Treatment
    • Drug Therapies
      • Antimetabolites
      • Antitumor Antibiotics
      • Asparagine-Specific Enzymes
      • Bisphosphonates & Biosimilars
      • DNA-Damaging Agents (Antineoplastics) and Alkylating Agents
      • Inhibitors
        • DNA-Repair Enzyme Inhibitors
        • Histone Deacetylase Inhibitors
        • Janus-Associated Kinase (JAK) Inhibitors
        • Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)
        • Proteasome Inhibitors
        • Tyrosine Kinase Inhibitors
        • PD-1 and PD-L1 inhibitors
        • Others
      • Monoclonal Antibodies
      • Others
    • Surgery
      • Open Surgery
      • Minimally Invasive Surgery
    • Radiation Therapy
    • Chemotherapy
    • Immunotherapy
      • Chimeric antigen receptor (CAR) T-cell therapy
      • Cytokine Treatment
      • Donor lymphocyte infusion
      • Monoclonal Antibody Treatment
      • Others
    • Targeted Therapy
    • Hormone Therapy
    • Stem Cell Transplant
      • Autologous stem cell transplantation
      • Allogeneic stem cell transplantation
      • Reduced-Intensity Allogeneic Stem Cell Transplantation
      • Graft-Versus-Host Disease
    • Precision Medicine
    • Others
  • By Geography
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Norway
        • Sweden
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxemburg
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

Key Questions

Request Sample

Report Customization

Request for Customization

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2017

1.2.2. Base Year: 2018

1.2.3. Forecast Years: 2019 – 2027

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Oncology Drugs Market

6. Market Synopsis:  Oncology Drugs Market

7. Oncology Drugs Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends in Oncology Drugs Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Oncology Drugs Market

7.6. Porter’s Five Force Analysis

8. Global Oncology Drugs Market Analysis and Forecasts, 2019 – 2027

8.1. Overview

8.1.1. Global Oncology Drugs Market Revenue (US$ Mn)

8.2. Global Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

8.2.1. Breast Cancer

8.2.1.1. Definition

8.2.1.2. Market Penetration, 2018

8.2.1.3. Market Estimation, 2013 – 2018

8.2.1.4. Market Forecast, 2019 – 2027

8.2.1.5. Compound Annual Growth Rate (CAGR)

8.2.1.6. Regional Bifurcation

8.2.1.6.1. North America

8.2.1.6.1.1. Market Estimation, 2013 – 2018

8.2.1.6.1.2. Market Forecast, 2019 – 2027

8.2.1.6.2. Europe

8.2.1.6.2.1. Market Estimation, 2013 – 2018

8.2.1.6.2.2. Market Forecast, 2019 – 2027

8.2.1.6.3. Asia Pacific

8.2.1.6.3.1. Market Estimation, 2013 – 2018

8.2.1.6.3.2. Market Forecast, 2019 – 2027

8.2.1.6.4. Middle East and Africa

8.2.1.6.4.1. Market Estimation, 2013 – 2018

8.2.1.6.4.2. Market Forecast, 2019 – 2027

8.2.1.6.5. Latin America

8.2.1.6.5.1. Market Estimation, 2013 – 2018

8.2.1.6.5.2. Market Forecast, 2019 – 2027

8.2.2. Prostate Cancer

8.2.2.1. Definition

8.2.2.2. Market Penetration, 2018

8.2.2.3. Market Estimation, 2013 – 2018

8.2.2.4. Market Forecast, 2019 – 2027

8.2.2.5. Compound Annual Growth Rate (CAGR)

8.2.2.6. Regional Bifurcation

8.2.2.6.1. North America

8.2.2.6.1.1. Market Estimation, 2013 – 2018

8.2.2.6.1.2. Market Forecast, 2019 – 2027

8.2.2.6.2. Europe

8.2.2.6.2.1. Market Estimation, 2013 – 2018

8.2.2.6.2.2. Market Forecast, 2019 – 2027

8.2.2.6.3. Asia Pacific

8.2.2.6.3.1. Market Estimation, 2013 – 2018

8.2.2.6.3.2. Market Forecast, 2019 – 2027

8.2.2.6.4. Middle East and Africa

8.2.2.6.4.1. Market Estimation, 2013 – 2018

8.2.2.6.4.2. Market Forecast, 2019 – 2027

8.2.2.6.5. Latin America

8.2.2.6.5.1. Market Estimation, 2013 – 2018

8.2.2.6.5.2. Market Forecast, 2019 – 2027

8.2.3. Basal Cell Cancer

8.2.3.1. Definition

8.2.3.2. Market Penetration, 2018

8.2.3.3. Market Estimation, 2013 – 2018

8.2.3.4. Market Forecast, 2019 – 2027

8.2.3.5. Compound Annual Growth Rate (CAGR)

8.2.3.6. Regional Bifurcation

8.2.3.6.1. North America

8.2.3.6.1.1. Market Estimation, 2013 – 2018

8.2.3.6.1.2. Market Forecast, 2019 – 2027

8.2.3.6.2. Europe

8.2.3.6.2.1. Market Estimation, 2013 – 2018

8.2.3.6.2.2. Market Forecast, 2019 – 2027

8.2.3.6.3. Asia Pacific

8.2.3.6.3.1. Market Estimation, 2013 – 2018

8.2.3.6.3.2. Market Forecast, 2019 – 2027

8.2.3.6.4. Middle East and Africa

8.2.3.6.4.1. Market Estimation, 2013 – 2018

8.2.3.6.4.2. Market Forecast, 2019 – 2027

8.2.3.6.5. Latin America

8.2.3.6.5.1. Market Estimation, 2013 – 2018

8.2.3.6.5.2. Market Forecast, 2019 – 2027

8.2.4. Skin Cancer (Non-Melanoma)

8.2.4.1. Definition

8.2.4.2. Market Penetration, 2018

8.2.4.3. Market Estimation, 2013 – 2018

8.2.4.4. Market Forecast, 2019 – 2027

8.2.4.5. Compound Annual Growth Rate (CAGR)

8.2.4.6. Regional Bifurcation

8.2.4.6.1. North America

8.2.4.6.1.1. Market Estimation, 2013 – 2018

8.2.4.6.1.2. Market Forecast, 2019 – 2027

8.2.4.6.2. Europe

8.2.4.6.2.1. Market Estimation, 2013 – 2018

8.2.4.6.2.2. Market Forecast, 2019 – 2027

8.2.4.6.3. Asia Pacific

8.2.4.6.3.1. Market Estimation, 2013 – 2018

8.2.4.6.3.2. Market Forecast, 2019 – 2027

8.2.4.6.4. Middle East and Africa

8.2.4.6.4.1. Market Estimation, 2013 – 2018

8.2.4.6.4.2. Market Forecast, 2019 – 2027

8.2.4.6.5. Latin America

8.2.4.6.5.1. Market Estimation, 2013 – 2018

8.2.4.6.5.2. Market Forecast, 2019 – 2027

8.2.5. Colorectal cancer

8.2.5.1. Definition

8.2.5.2. Market Penetration, 2018

8.2.5.3. Market Estimation, 2013 – 2018

8.2.5.4. Market Forecast, 2019 – 2027

8.2.5.5. Compound Annual Growth Rate (CAGR)

8.2.5.6. Regional Bifurcation

8.2.5.6.1. North America

8.2.5.6.1.1. Market Estimation, 2013 – 2018

8.2.5.6.1.2. Market Forecast, 2019 – 2027

8.2.5.6.2. Europe

8.2.5.6.2.1. Market Estimation, 2013 – 2018

8.2.5.6.2.2. Market Forecast, 2019 – 2027

8.2.5.6.3. Asia Pacific

8.2.5.6.3.1. Market Estimation, 2013 – 2018

8.2.5.6.3.2. Market Forecast, 2019 – 2027

8.2.5.6.4. Middle East and Africa

8.2.5.6.4.1. Market Estimation, 2013 – 2018

8.2.5.6.4.2. Market Forecast, 2019 – 2027

8.2.5.6.5. Latin America

8.2.5.6.5.1. Market Estimation, 2013 – 2018

8.2.5.6.5.2. Market Forecast, 2019 – 2027

8.2.6. Lung Cancer

8.2.6.1. Definition

8.2.6.2. Market Penetration, 2018

8.2.6.3. Market Estimation, 2013 – 2018

8.2.6.4. Market Forecast, 2019 – 2027

8.2.6.5. Compound Annual Growth Rate (CAGR)

8.2.6.6. Regional Bifurcation

8.2.6.6.1. North America

8.2.6.6.1.1. Market Estimation, 2013 – 2018

8.2.6.6.1.2. Market Forecast, 2019 – 2027

8.2.6.6.2. Europe

8.2.6.6.2.1. Market Estimation, 2013 – 2018

8.2.6.6.2.2. Market Forecast, 2019 – 2027

8.2.6.6.3. Asia Pacific

8.2.6.6.3.1. Market Estimation, 2013 – 2018

8.2.6.6.3.2. Market Forecast, 2019 – 2027

8.2.6.6.4. Middle East and Africa

8.2.6.6.4.1. Market Estimation, 2013 – 2018

8.2.6.6.4.2. Market Forecast, 2019 – 2027

8.2.6.6.5. Latin America

8.2.6.6.5.1. Market Estimation, 2013 – 2018

8.2.6.6.5.2. Market Forecast, 2019 – 2027

8.2.7. Renal Cancer

8.2.7.1. Definition

8.2.7.2. Market Penetration, 2018

8.2.7.3. Market Estimation, 2013 – 2018

8.2.7.4. Market Forecast, 2019 – 2027

8.2.7.5. Compound Annual Growth Rate (CAGR)

8.2.7.6. Regional Bifurcation

8.2.7.6.1. North America

8.2.7.6.1.1. Market Estimation, 2013 – 2018

8.2.7.6.1.2. Market Forecast, 2019 – 2027

8.2.7.6.2. Europe

8.2.7.6.2.1. Market Estimation, 2013 – 2018

8.2.7.6.2.2. Market Forecast, 2019 – 2027

8.2.7.6.3. Asia Pacific

8.2.7.6.3.1. Market Estimation, 2013 – 2018

8.2.7.6.3.2. Market Forecast, 2019 – 2027

8.2.7.6.4. Middle East and Africa

8.2.7.6.4.1. Market Estimation, 2013 – 2018

8.2.7.6.4.2. Market Forecast, 2019 – 2027

8.2.7.6.5. Latin America

8.2.7.6.5.1. Market Estimation, 2013 – 2018

8.2.7.6.5.2. Market Forecast, 2019 – 2027

8.2.8. Bladder Cancer

8.2.8.1. Definition

8.2.8.2. Market Penetration, 2018

8.2.8.3. Market Estimation, 2013 – 2018

8.2.8.4. Market Forecast, 2019 – 2027

8.2.8.5. Compound Annual Growth Rate (CAGR)

8.2.8.6. Regional Bifurcation

8.2.8.6.1. North America

8.2.8.6.1.1. Market Estimation, 2013 – 2018

8.2.8.6.1.2. Market Forecast, 2019 – 2027

8.2.8.6.2. Europe

8.2.8.6.2.1. Market Estimation, 2013 – 2018

8.2.8.6.2.2. Market Forecast, 2019 – 2027

8.2.8.6.3. Asia Pacific

8.2.8.6.3.1. Market Estimation, 2013 – 2018

8.2.8.6.3.2. Market Forecast, 2019 – 2027

8.2.8.6.4. Middle East and Africa

8.2.8.6.4.1. Market Estimation, 2013 – 2018

8.2.8.6.4.2. Market Forecast, 2019 – 2027

8.2.8.6.5. Latin America

8.2.8.6.5.1. Market Estimation, 2013 – 2018

8.2.8.6.5.2. Market Forecast, 2019 – 2027

8.2.9. Lymphoma

8.2.9.1. Definition

8.2.9.2. Market Penetration, 2018

8.2.9.3. Market Estimation, 2013 – 2018

8.2.9.4. Market Forecast, 2019 – 2027

8.2.9.5. Compound Annual Growth Rate (CAGR)

8.2.9.6. Regional Bifurcation

8.2.9.6.1. North America

8.2.9.6.1.1. Market Estimation, 2013 – 2018

8.2.9.6.1.2. Market Forecast, 2019 – 2027

8.2.9.6.2. Europe

8.2.9.6.2.1. Market Estimation, 2013 – 2018

8.2.9.6.2.2. Market Forecast, 2019 – 2027

8.2.9.6.3. Asia Pacific

8.2.9.6.3.1. Market Estimation, 2013 – 2018

8.2.9.6.3.2. Market Forecast, 2019 – 2027

8.2.9.6.4. Middle East and Africa

8.2.9.6.4.1. Market Estimation, 2013 – 2018

8.2.9.6.4.2. Market Forecast, 2019 – 2027

8.2.9.6.5. Latin America

8.2.9.6.5.1. Market Estimation, 2013 – 2018

8.2.9.6.5.2. Market Forecast, 2019 – 2027

8.2.10. Others

8.2.10.1. Definition

8.2.10.2. Market Penetration, 2018

8.2.10.3. Market Estimation, 2013 – 2018

8.2.10.4. Market Forecast, 2019 – 2027

8.2.10.5. Compound Annual Growth Rate (CAGR)

8.2.10.6. Regional Bifurcation

8.2.10.6.1. North America

8.2.10.6.1.1. Market Estimation, 2013 – 2018

8.2.10.6.1.2. Market Forecast, 2019 – 2027

8.2.10.6.2. Europe

8.2.10.6.2.1. Market Estimation, 2013 – 2018

8.2.10.6.2.2. Market Forecast, 2019 – 2027

8.2.10.6.3. Asia Pacific

8.2.10.6.3.1. Market Estimation, 2013 – 2018

8.2.10.6.3.2. Market Forecast, 2019 – 2027

8.2.10.6.4. Middle East and Africa

8.2.10.6.4.1. Market Estimation, 2013 – 2018

8.2.10.6.4.2. Market Forecast, 2019 – 2027

8.2.10.6.5. Latin America

8.2.10.6.5.1. Market Estimation, 2013 – 2018

8.2.10.6.5.2. Market Forecast, 2019 – 2027

8.3. Key Segment for Channeling Investments

8.3.1. By Indication

9. Global Oncology Drugs Market Analysis and Forecasts, 2019 – 2027

9.1. Overview

9.2. Global Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

9.2.1. Drug Therapies (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Antimetabolites, Antitumor Antibiotics, Asparagine-Specific Enzymes, Bisphosphonates and Biosimilars, DNA-Damaging Agents (Antineoplastics) and Alkylating Agents, Inhibitors, Monoclonal Antibodies, Others)

9.2.1.1. Antimetabolites

9.2.1.2. Antitumor Antibiotics

9.2.1.3. Asparagine-Specific Enzymes

9.2.1.4. Bisphosphonates and Biosimilars

9.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

9.2.1.6. Inhibitors

9.2.1.6.1. DNA-Repair Enzyme Inhibitors

9.2.1.6.2. Histone Deacetylase Inhibitors

9.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

9.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

9.2.1.6.5. Proteasome Inhibitors

9.2.1.6.6. Tyrosine Kinase Inhibitors

9.2.1.6.7. PD-1 and PD-L1 inhibitors

9.2.1.6.8. Others

9.2.1.7. Monoclonal Antibodies

9.2.1.8. Others

9.2.2. Surgery (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Open Surgery, Minimally Invasive Surgery)

9.2.2.1. Open Surgery

9.2.2.2. Minimally Invasive Surgery

9.2.3. Radiation Therapy

9.2.3.1. Definition

9.2.3.2. Market Penetration, 2018

9.2.3.3. Market Estimation, 2013 – 2018

9.2.3.4. Market Forecast, 2019 – 2027

9.2.3.5. Compound Annual Growth Rate (CAGR)

9.2.3.6. Regional Bifurcation

9.2.3.6.1. North America

9.2.3.6.1.1. Market Estimation, 2013 – 2018

9.2.3.6.1.2. Market Forecast, 2019 – 2027

9.2.3.6.2. Europe

9.2.3.6.2.1. Market Estimation, 2013 – 2018

9.2.3.6.2.2. Market Forecast, 2019 – 2027

9.2.3.6.3. Asia Pacific

9.2.3.6.3.1. Market Estimation, 2013 – 2018

9.2.3.6.3.2. Market Forecast, 2019 – 2027

9.2.3.6.4. Middle East and Africa

9.2.3.6.4.1. Market Estimation, 2013 – 2018

9.2.3.6.4.2. Market Forecast, 2019 – 2027

9.2.3.6.5. Latin America

9.2.3.6.5.1. Market Estimation, 2013 – 2018

9.2.3.6.5.2. Market Forecast, 2019 – 2027

9.2.4. Chemotherapy

9.2.4.1. Definition

9.2.4.2. Market Penetration, 2018

9.2.4.3. Market Estimation, 2013 – 2018

9.2.4.4. Market Forecast, 2019 – 2027

9.2.4.5. Compound Annual Growth Rate (CAGR)

9.2.4.6. Regional Bifurcation

9.2.4.6.1. North America

9.2.4.6.1.1. Market Estimation, 2013 – 2018

9.2.4.6.1.2. Market Forecast, 2019 – 2027

9.2.4.6.2. Europe

9.2.4.6.2.1. Market Estimation, 2013 – 2018

9.2.4.6.2.2. Market Forecast, 2019 – 2027

9.2.4.6.3. Asia Pacific

9.2.4.6.3.1. Market Estimation, 2013 – 2018

9.2.4.6.3.2. Market Forecast, 2019 – 2027

9.2.4.6.4. Middle East and Africa

9.2.4.6.4.1. Market Estimation, 2013 – 2018

9.2.4.6.4.2. Market Forecast, 2019 – 2027

9.2.4.6.5. Latin America

9.2.4.6.5.1. Market Estimation, 2013 – 2018

9.2.4.6.5.2. Market Forecast, 2019 – 2027

9.2.5. Immunotherapy (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Chimeric antigen receptor (CAR) T-cell therapy, Cytokine Treatment, Donor lymphocyte infusion, Monoclonal Antibody Treatment, Others)

9.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

9.2.5.2. Cytokine Treatment

9.2.5.3. Donor lymphocyte infusion

9.2.5.4. Monoclonal Antibody Treatment

9.2.5.5. Others

9.2.6. Targeted Therapy

9.2.6.1. Definition

9.2.6.2. Market Penetration, 2018

9.2.6.3. Market Estimation, 2013 – 2018

9.2.6.4. Market Forecast, 2019 – 2027

9.2.6.5. Compound Annual Growth Rate (CAGR)

9.2.6.6. Regional Bifurcation

9.2.6.6.1. North America

9.2.6.6.1.1. Market Estimation, 2013 – 2018

9.2.6.6.1.2. Market Forecast, 2019 – 2027

9.2.6.6.2. Europe

9.2.6.6.2.1. Market Estimation, 2013 – 2018

9.2.6.6.2.2. Market Forecast, 2019 – 2027

9.2.6.6.3. Asia Pacific

9.2.6.6.3.1. Market Estimation, 2013 – 2018

9.2.6.6.3.2. Market Forecast, 2019 – 2027

9.2.6.6.4. Middle East and Africa

9.2.6.6.4.1. Market Estimation, 2013 – 2018

9.2.6.6.4.2. Market Forecast, 2019 – 2027

9.2.6.6.5. Latin America

9.2.6.6.5.1. Market Estimation, 2013 – 2018

9.2.6.6.5.2. Market Forecast, 2019 – 2027

9.2.7. Hormone Therapy

9.2.7.1. Definition

9.2.7.2. Market Penetration, 2018

9.2.7.3. Market Estimation, 2013 – 2018

9.2.7.4. Market Forecast, 2019 – 2027

9.2.7.5. Compound Annual Growth Rate (CAGR)

9.2.7.6. Regional Bifurcation

9.2.7.6.1. North America

9.2.7.6.1.1. Market Estimation, 2013 – 2018

9.2.7.6.1.2. Market Forecast, 2019 – 2027

9.2.7.6.2. Europe

9.2.7.6.2.1. Market Estimation, 2013 – 2018

9.2.7.6.2.2. Market Forecast, 2019 – 2027

9.2.7.6.3. Asia Pacific

9.2.7.6.3.1. Market Estimation, 2013 – 2018

9.2.7.6.3.2. Market Forecast, 2019 – 2027

9.2.7.6.4. Middle East and Africa

9.2.7.6.4.1. Market Estimation, 2013 – 2018

9.2.7.6.4.2. Market Forecast, 2019 – 2027

9.2.7.6.5. Latin America

9.2.7.6.5.1. Market Estimation, 2013 – 2018

9.2.7.6.5.2. Market Forecast, 2019 – 2027

9.2.8. Stem Cell Therapy (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Autologous stem cell transplantation, Allogeneic stem cell transplantation, Reduced-Intensity Allogeneic Stem Cell Transplantation, Graft-Versus-Host Disease)

9.2.8.1. Autologous stem cell transplantation

9.2.8.2. Allogeneic stem cell transplantation

9.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

9.2.8.4. Graft-Versus-Host Disease

9.2.9. Precision Medicine

9.2.9.1. Definition

9.2.9.2. Market Penetration, 2018

9.2.9.3. Market Estimation, 2013 – 2018

9.2.9.4. Market Forecast, 2019 – 2027

9.2.9.5. Compound Annual Growth Rate (CAGR)

9.2.9.6. Regional Bifurcation

9.2.9.6.1. North America

9.2.9.6.1.1. Market Estimation, 2013 – 2018

9.2.9.6.1.2. Market Forecast, 2019 – 2027

9.2.9.6.2. Europe

9.2.9.6.2.1. Market Estimation, 2013 – 2018

9.2.9.6.2.2. Market Forecast, 2019 – 2027

9.2.9.6.3. Asia Pacific

9.2.9.6.3.1. Market Estimation, 2013 – 2018

9.2.9.6.3.2. Market Forecast, 2019 – 2027

9.2.9.6.4. Middle East and Africa

9.2.9.6.4.1. Market Estimation, 2013 – 2018

9.2.9.6.4.2. Market Forecast, 2019 – 2027

9.2.9.6.5. Latin America

9.2.9.6.5.1. Market Estimation, 2013 – 2018

9.2.9.6.5.2. Market Forecast, 2019 – 2027

9.2.10. Others

9.2.10.1. Definition

9.2.10.2. Market Penetration, 2018

9.2.10.3. Market Estimation, 2013 – 2018

9.2.10.4. Market Forecast, 2019 – 2027

9.2.10.5. Compound Annual Growth Rate (CAGR)

9.2.10.6. Regional Bifurcation

9.2.10.6.1. North America

9.2.10.6.1.1. Market Estimation, 2013 – 2018

9.2.10.6.1.2. Market Forecast, 2019 – 2027

9.2.10.6.2. Europe

9.2.10.6.2.1. Market Estimation, 2013 – 2018

9.2.10.6.2.2. Market Forecast, 2019 – 2027

9.2.10.6.3. Asia Pacific

9.2.10.6.3.1. Market Estimation, 2013 – 2018

9.2.10.6.3.2. Market Forecast, 2019 – 2027

9.2.10.6.4. Middle East and Africa

9.2.10.6.4.1. Market Estimation, 2013 – 2018

9.2.10.6.4.2. Market Forecast, 2019 – 2027

9.2.10.6.5. Latin America

9.2.10.6.5.1. Market Estimation, 2013 – 2018

9.2.10.6.5.2. Market Forecast, 2019 – 2027

9.3. Key Segment for Channeling Investments

9.3.1. By Treatment

10. North America Oncology Drugs Market Analysis and Forecasts, 2019 - 2027

10.1. Overview

10.1.1. North America Oncology Drugs Market Revenue (US$ Mn)

10.2. North America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

10.2.1. Breast Cancer

10.2.2. Prostate Cancer

10.2.3. Basal Cell Cancer

10.2.4. Skin Cancer (Non-Melanoma)

10.2.5. Colorectal cancer

10.2.6. Lung Cancer

10.2.7. Renal Cancer

10.2.8. Bladder Cancer

10.2.9. Lymphoma

10.2.10. Others

10.3. North America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

10.3.1. Drug Therapies

10.3.1.1. Antimetabolites

10.3.1.2. Antitumor Antibiotics

10.3.1.3. Asparagine-Specific Enzymes

10.3.1.4. Bisphosphonates and Biosimilars

10.3.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

10.3.1.6. Inhibitors

10.3.1.6.1. DNA-Repair Enzyme Inhibitors

10.3.1.6.2. Histone Deacetylase Inhibitors

10.3.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

10.3.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

10.3.1.6.5. Proteasome Inhibitors

10.3.1.6.6. Tyrosine Kinase Inhibitors

10.3.1.6.7. PD-1 and PD-L1 inhibitors

10.3.1.6.8. Others

10.3.1.7. Monoclonal Antibodies

10.3.1.8. Others

10.3.2. Surgery

10.3.2.1. Open Surgery

10.3.2.2. Minimally Invasive Surgery

10.3.3. Radiation Therapy

10.3.4. Chemotherapy

10.3.5. Immunotherapy

10.3.5.1. Chimeric antigen receptor (CAR) T-cell therapy

10.3.5.2. Cytokine Treatment

10.3.5.3. Donor lymphocyte infusion

10.3.5.4. Monoclonal Antibody Treatment

10.3.5.5. Others

10.3.6. Targeted Therapy

10.3.7. Hormone Therapy

10.3.8. Stem Cell Therapy

10.3.8.1. Autologous stem cell transplantation

10.3.8.2. Allogeneic stem cell transplantation

10.3.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

10.3.8.4. Graft-Versus-Host Disease

10.3.9. Precision Medicine

10.3.10. Others

10.4. North America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. U.S

10.4.1.1. U.S Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

10.4.1.1.1. Breast Cancer

10.4.1.1.2. Prostate Cancer

10.4.1.1.3. Basal Cell Cancer

10.4.1.1.4. Skin Cancer (Non-Melanoma)

10.4.1.1.5. Colorectal cancer

10.4.1.1.6. Lung Cancer

10.4.1.1.7. Renal Cancer

10.4.1.1.8. Bladder Cancer

10.4.1.1.9. Lymphoma

10.4.1.1.10. Others

10.4.1.2. U.S Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

10.4.1.2.1. Drug Therapies

10.4.1.2.1.1. Antimetabolites

10.4.1.2.1.2. Antitumor Antibiotics

10.4.1.2.1.3. Asparagine-Specific Enzymes

10.4.1.2.1.4. Bisphosphonates and Biosimilars

10.4.1.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

10.4.1.2.1.6. Inhibitors

10.4.1.2.1.6.1. DNA-Repair Enzyme Inhibitors

10.4.1.2.1.6.2. Histone Deacetylase Inhibitors

10.4.1.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

10.4.1.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

10.4.1.2.1.6.5. Proteasome Inhibitors

10.4.1.2.1.6.6. Tyrosine Kinase Inhibitors

10.4.1.2.1.6.7. PD-1 and PD-L1 inhibitors

10.4.1.2.1.6.8. Others

10.4.1.2.1.7. Monoclonal Antibodies

10.4.1.2.1.8. Others

10.4.1.2.2. Surgery

10.4.1.2.2.1. Open Surgery

10.4.1.2.2.2. Minimally Invasive Surgery

10.4.1.2.3. Radiation Therapy

10.4.1.2.4. Chemotherapy

10.4.1.2.5. Immunotherapy

10.4.1.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

10.4.1.2.5.2. Cytokine Treatment

10.4.1.2.5.3. Donor lymphocyte infusion

10.4.1.2.5.4. Monoclonal Antibody Treatment

10.4.1.2.5.5. Others

10.4.1.2.6. Targeted Therapy

10.4.1.2.7. Hormone Therapy

10.4.1.2.8. Stem Cell Therapy

10.4.1.2.8.1. Autologous stem cell transplantation

10.4.1.2.8.2. Allogeneic stem cell transplantation

10.4.1.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

10.4.1.2.8.4. Graft-Versus-Host Disease

10.4.1.2.9. Precision Medicine

10.4.1.2.10. Others

10.4.2. Canada

10.4.2.1. Canada Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

10.4.2.1.1. Breast Cancer

10.4.2.1.2. Prostate Cancer

10.4.2.1.3. Basal Cell Cancer

10.4.2.1.4. Skin Cancer (Non-Melanoma)

10.4.2.1.5. Colorectal cancer

10.4.2.1.6. Lung Cancer

10.4.2.1.7. Renal Cancer

10.4.2.1.8. Bladder Cancer

10.4.2.1.9. Lymphoma

10.4.2.1.10. Others

10.4.2.2. Canada Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

10.4.2.2.1. Drug Therapies

10.4.2.2.1.1. Antimetabolites

10.4.2.2.1.2. Antitumor Antibiotics

10.4.2.2.1.3. Asparagine-Specific Enzymes

10.4.2.2.1.4. Bisphosphonates and Biosimilars

10.4.2.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

10.4.2.2.1.6. Inhibitors

10.4.2.2.1.6.1. DNA-Repair Enzyme Inhibitors

10.4.2.2.1.6.2. Histone Deacetylase Inhibitors

10.4.2.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

10.4.2.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

10.4.2.2.1.6.5. Proteasome Inhibitors

10.4.2.2.1.6.6. Tyrosine Kinase Inhibitors

10.4.2.2.1.6.7. PD-1 and PD-L1 inhibitors

10.4.2.2.1.6.8. Others

10.4.2.2.1.7. Monoclonal Antibodies

10.4.2.2.1.8. Others

10.4.2.2.2. Surgery

10.4.2.2.2.1. Open Surgery

10.4.2.2.2.2. Minimally Invasive Surgery

10.4.2.2.3. Radiation Therapy

10.4.2.2.4. Chemotherapy

10.4.2.2.5. Immunotherapy

10.4.2.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

10.4.2.2.5.2. Cytokine Treatment

10.4.2.2.5.3. Donor lymphocyte infusion

10.4.2.2.5.4. Monoclonal Antibody Treatment

10.4.2.2.5.5. Others

10.4.2.2.6. Targeted Therapy

10.4.2.2.7. Hormone Therapy

10.4.2.2.8. Stem Cell Therapy

10.4.2.2.8.1. Autologous stem cell transplantation

10.4.2.2.8.2. Allogeneic stem cell transplantation

10.4.2.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

10.4.2.2.8.4. Graft-Versus-Host Disease

10.4.2.2.9. Precision Medicine

10.4.2.2.10. Others

10.4.3. Mexico

10.4.3.1. Mexico Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

10.4.3.1.1. Breast Cancer

10.4.3.1.2. Prostate Cancer

10.4.3.1.3. Basal Cell Cancer

10.4.3.1.4. Skin Cancer (Non-Melanoma)

10.4.3.1.5. Colorectal cancer

10.4.3.1.6. Lung Cancer

10.4.3.1.7. Renal Cancer

10.4.3.1.8. Bladder Cancer

10.4.3.1.9. Lymphoma

10.4.3.1.10. Others

10.4.3.2. Mexico Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

10.4.3.2.1. Drug Therapies

10.4.3.2.1.1. Antimetabolites

10.4.3.2.1.2. Antitumor Antibiotics

10.4.3.2.1.3. Asparagine-Specific Enzymes

10.4.3.2.1.4. Bisphosphonates and Biosimilars

10.4.3.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

10.4.3.2.1.6. Inhibitors

10.4.3.2.1.6.1. DNA-Repair Enzyme Inhibitors

10.4.3.2.1.6.2. Histone Deacetylase Inhibitors

10.4.3.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

10.4.3.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

10.4.3.2.1.6.5. Proteasome Inhibitors

10.4.3.2.1.6.6. Tyrosine Kinase Inhibitors

10.4.3.2.1.6.7. PD-1 and PD-L1 inhibitors

10.4.3.2.1.6.8. Others

10.4.3.2.1.7. Monoclonal Antibodies

10.4.3.2.1.8. Others

10.4.3.2.2. Surgery

10.4.3.2.2.1. Open Surgery

10.4.3.2.2.2. Minimally Invasive Surgery

10.4.3.2.3. Radiation Therapy

10.4.3.2.4. Chemotherapy

10.4.3.2.5. Immunotherapy

10.4.3.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

10.4.3.2.5.2. Cytokine Treatment

10.4.3.2.5.3. Donor lymphocyte infusion

10.4.3.2.5.4. Monoclonal Antibody Treatment

10.4.3.2.5.5. Others

10.4.3.2.6. Targeted Therapy

10.4.3.2.7. Hormone Therapy

10.4.3.2.8. Stem Cell Therapy

10.4.3.2.8.1. Autologous stem cell transplantation

10.4.3.2.8.2. Allogeneic stem cell transplantation

10.4.3.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

10.4.3.2.8.4. Graft-Versus-Host Disease

10.4.3.2.9. Precision Medicine

10.4.3.2.10. Others

10.4.4. Rest of North America

10.4.4.1. Rest of North America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

10.4.4.1.1. Breast Cancer

10.4.4.1.2. Prostate Cancer

10.4.4.1.3. Basal Cell Cancer

10.4.4.1.4. Skin Cancer (Non-Melanoma)

10.4.4.1.5. Colorectal cancer

10.4.4.1.6. Lung Cancer

10.4.4.1.7. Renal Cancer

10.4.4.1.8. Bladder Cancer

10.4.4.1.9. Lymphoma

10.4.4.1.10. Others

10.4.4.2. Rest of North America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

10.4.4.2.1. Drug Therapies

10.4.4.2.1.1. Antimetabolites

10.4.4.2.1.2. Antitumor Antibiotics

10.4.4.2.1.3. Asparagine-Specific Enzymes

10.4.4.2.1.4. Bisphosphonates and Biosimilars

10.4.4.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

10.4.4.2.1.6. Inhibitors

10.4.4.2.1.6.1. DNA-Repair Enzyme Inhibitors

10.4.4.2.1.6.2. Histone Deacetylase Inhibitors

10.4.4.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

10.4.4.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

10.4.4.2.1.6.5. Proteasome Inhibitors

10.4.4.2.1.6.6. Tyrosine Kinase Inhibitors

10.4.4.2.1.6.7. PD-1 and PD-L1 inhibitors

10.4.4.2.1.6.8. Others

10.4.4.2.1.7. Monoclonal Antibodies

10.4.4.2.1.8. Others

10.4.4.2.2. Surgery

10.4.4.2.2.1. Open Surgery

10.4.4.2.2.2. Minimally Invasive Surgery

10.4.4.2.3. Radiation Therapy

10.4.4.2.4. Chemotherapy

10.4.4.2.5. Immunotherapy

10.4.4.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

10.4.4.2.5.2. Cytokine Treatment

10.4.4.2.5.3. Donor lymphocyte infusion

10.4.4.2.5.4. Monoclonal Antibody Treatment

10.4.4.2.5.5. Others

10.4.4.2.6. Targeted Therapy

10.4.4.2.7. Hormone Therapy

10.4.4.2.8. Stem Cell Therapy

10.4.4.2.8.1. Autologous stem cell transplantation

10.4.4.2.8.2. Allogeneic stem cell transplantation

10.4.4.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

10.4.4.2.8.4. Graft-Versus-Host Disease

10.4.4.2.9. Precision Medicine

10.4.4.2.10. Others

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Indication

10.5.3. By Treatment

11. Europe Oncology Drugs Market Analysis and Forecasts, 2019 - 2027

11.1. Overview

11.1.1. Europe Oncology Drugs Market Revenue (US$ Mn)

11.2. Europe Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.2.1. Breast Cancer

11.2.2. Prostate Cancer

11.2.3. Basal Cell Cancer

11.2.4. Skin Cancer (Non-Melanoma)

11.2.5. Colorectal cancer

11.2.6. Lung Cancer

11.2.7. Renal Cancer

11.2.8. Bladder Cancer

11.2.9. Lymphoma

11.2.10. Others

11.3. Europe Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.3.1. Drug Therapies

11.3.1.1. Antimetabolites

11.3.1.2. Antitumor Antibiotics

11.3.1.3. Asparagine-Specific Enzymes

11.3.1.4. Bisphosphonates and Biosimilars

11.3.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.3.1.6. Inhibitors

11.3.1.6.1. DNA-Repair Enzyme Inhibitors

11.3.1.6.2. Histone Deacetylase Inhibitors

11.3.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.3.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.3.1.6.5. Proteasome Inhibitors

11.3.1.6.6. Tyrosine Kinase Inhibitors

11.3.1.6.7. PD-1 and PD-L1 inhibitors

11.3.1.6.8. Others

11.3.1.7. Monoclonal Antibodies

11.3.1.8. Others

11.3.2. Surgery

11.3.2.1. Open Surgery

11.3.2.2. Minimally Invasive Surgery

11.3.3. Radiation Therapy

11.3.4. Chemotherapy

11.3.5. Immunotherapy

11.3.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.3.5.2. Cytokine Treatment

11.3.5.3. Donor lymphocyte infusion

11.3.5.4. Monoclonal Antibody Treatment

11.3.5.5. Others

11.3.6. Targeted Therapy

11.3.7. Hormone Therapy

11.3.8. Stem Cell Therapy

11.3.8.1. Autologous stem cell transplantation

11.3.8.2. Allogeneic stem cell transplantation

11.3.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.3.8.4. Graft-Versus-Host Disease

11.3.9. Precision Medicine

11.3.10. Others

11.4. Europe Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. France

11.4.1.1. France Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.1.1.1. Breast Cancer

11.4.1.1.2. Prostate Cancer

11.4.1.1.3. Basal Cell Cancer

11.4.1.1.4. Skin Cancer (Non-Melanoma)

11.4.1.1.5. Colorectal cancer

11.4.1.1.6. Lung Cancer

11.4.1.1.7. Renal Cancer

11.4.1.1.8. Bladder Cancer

11.4.1.1.9. Lymphoma

11.4.1.1.10. Others

11.4.1.2. France Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.1.2.1. Drug Therapies

11.4.1.2.1.1. Antimetabolites

11.4.1.2.1.2. Antitumor Antibiotics

11.4.1.2.1.3. Asparagine-Specific Enzymes

11.4.1.2.1.4. Bisphosphonates and Biosimilars

11.4.1.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.1.2.1.6. Inhibitors

11.4.1.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.1.2.1.6.2. Histone Deacetylase Inhibitors

11.4.1.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.1.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.1.2.1.6.5. Proteasome Inhibitors

11.4.1.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.1.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.1.2.1.6.8. Others

11.4.1.2.1.7. Monoclonal Antibodies

11.4.1.2.1.8. Others

11.4.1.2.2. Surgery

11.4.1.2.2.1. Open Surgery

11.4.1.2.2.2. Minimally Invasive Surgery

11.4.1.2.3. Radiation Therapy

11.4.1.2.4. Chemotherapy

11.4.1.2.5. Immunotherapy

11.4.1.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.1.2.5.2. Cytokine Treatment

11.4.1.2.5.3. Donor lymphocyte infusion

11.4.1.2.5.4. Monoclonal Antibody Treatment

11.4.1.2.5.5. Others

11.4.1.2.6. Targeted Therapy

11.4.1.2.7. Hormone Therapy

11.4.1.2.8. Stem Cell Therapy

11.4.1.2.8.1. Autologous stem cell transplantation

11.4.1.2.8.2. Allogeneic stem cell transplantation

11.4.1.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.1.2.8.4. Graft-Versus-Host Disease

11.4.1.2.9. Precision Medicine

11.4.1.2.10. Others

11.4.2. The UK

11.4.2.1. The UK Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.2.1.1. Breast Cancer

11.4.2.1.2. Prostate Cancer

11.4.2.1.3. Basal Cell Cancer

11.4.2.1.4. Skin Cancer (Non-Melanoma)

11.4.2.1.5. Colorectal cancer

11.4.2.1.6. Lung Cancer

11.4.2.1.7. Renal Cancer

11.4.2.1.8. Bladder Cancer

11.4.2.1.9. Lymphoma

11.4.2.1.10. Others

11.4.2.2. The UK Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.2.2.1. Drug Therapies

11.4.2.2.1.1. Antimetabolites

11.4.2.2.1.2. Antitumor Antibiotics

11.4.2.2.1.3. Asparagine-Specific Enzymes

11.4.2.2.1.4. Bisphosphonates and Biosimilars

11.4.2.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.2.2.1.6. Inhibitors

11.4.2.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.2.2.1.6.2. Histone Deacetylase Inhibitors

11.4.2.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.2.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.2.2.1.6.5. Proteasome Inhibitors

11.4.2.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.2.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.2.2.1.6.8. Others

11.4.2.2.1.7. Monoclonal Antibodies

11.4.2.2.1.8. Others

11.4.2.2.2. Surgery

11.4.2.2.2.1. Open Surgery

11.4.2.2.2.2. Minimally Invasive Surgery

11.4.2.2.3. Radiation Therapy

11.4.2.2.4. Chemotherapy

11.4.2.2.5. Immunotherapy

11.4.2.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.2.2.5.2. Cytokine Treatment

11.4.2.2.5.3. Donor lymphocyte infusion

11.4.2.2.5.4. Monoclonal Antibody Treatment

11.4.2.2.5.5. Others

11.4.2.2.6. Targeted Therapy

11.4.2.2.7. Hormone Therapy

11.4.2.2.8. Stem Cell Therapy

11.4.2.2.8.1. Autologous stem cell transplantation

11.4.2.2.8.2. Allogeneic stem cell transplantation

11.4.2.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.2.2.8.4. Graft-Versus-Host Disease

11.4.2.2.9. Precision Medicine

11.4.2.2.10. Others

11.4.3. Spain

11.4.3.1. Spain Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.3.1.1. Breast Cancer

11.4.3.1.2. Prostate Cancer

11.4.3.1.3. Basal Cell Cancer

11.4.3.1.4. Skin Cancer (Non-Melanoma)

11.4.3.1.5. Colorectal cancer

11.4.3.1.6. Lung Cancer

11.4.3.1.7. Renal Cancer

11.4.3.1.8. Bladder Cancer

11.4.3.1.9. Lymphoma

11.4.3.1.10. Others

11.4.3.2. Spain Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.3.2.1. Drug Therapies

11.4.3.2.1.1. Antimetabolites

11.4.3.2.1.2. Antitumor Antibiotics

11.4.3.2.1.3. Asparagine-Specific Enzymes

11.4.3.2.1.4. Bisphosphonates and Biosimilars

11.4.3.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.3.2.1.6. Inhibitors

11.4.3.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.3.2.1.6.2. Histone Deacetylase Inhibitors

11.4.3.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.3.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.3.2.1.6.5. Proteasome Inhibitors

11.4.3.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.3.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.3.2.1.6.8. Others

11.4.3.2.1.7. Monoclonal Antibodies

11.4.3.2.1.8. Others

11.4.3.2.2. Surgery

11.4.3.2.2.1. Open Surgery

11.4.3.2.2.2. Minimally Invasive Surgery

11.4.3.2.3. Radiation Therapy

11.4.3.2.4. Chemotherapy

11.4.3.2.5. Immunotherapy

11.4.3.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.3.2.5.2. Cytokine Treatment

11.4.3.2.5.3. Donor lymphocyte infusion

11.4.3.2.5.4. Monoclonal Antibody Treatment

11.4.3.2.5.5. Others

11.4.3.2.6. Targeted Therapy

11.4.3.2.7. Hormone Therapy

11.4.3.2.8. Stem Cell Therapy

11.4.3.2.8.1. Autologous stem cell transplantation

11.4.3.2.8.2. Allogeneic stem cell transplantation

11.4.3.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.3.2.8.4. Graft-Versus-Host Disease

11.4.3.2.9. Precision Medicine

11.4.3.2.10. Others

11.4.4. Germany

11.4.4.1. Germany Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.4.1.1. Breast Cancer

11.4.4.1.2. Prostate Cancer

11.4.4.1.3. Basal Cell Cancer

11.4.4.1.4. Skin Cancer (Non-Melanoma)

11.4.4.1.5. Colorectal cancer

11.4.4.1.6. Lung Cancer

11.4.4.1.7. Renal Cancer

11.4.4.1.8. Bladder Cancer

11.4.4.1.9. Lymphoma

11.4.4.1.10. Others

11.4.4.2. Germany Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.4.2.1. Drug Therapies

11.4.4.2.1.1. Antimetabolites

11.4.4.2.1.2. Antitumor Antibiotics

11.4.4.2.1.3. Asparagine-Specific Enzymes

11.4.4.2.1.4. Bisphosphonates and Biosimilars

11.4.4.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.4.2.1.6. Inhibitors

11.4.4.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.4.2.1.6.2. Histone Deacetylase Inhibitors

11.4.4.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.4.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.4.2.1.6.5. Proteasome Inhibitors

11.4.4.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.4.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.4.2.1.6.8. Others

11.4.4.2.1.7. Monoclonal Antibodies

11.4.4.2.1.8. Others

11.4.4.2.2. Surgery

11.4.4.2.2.1. Open Surgery

11.4.4.2.2.2. Minimally Invasive Surgery

11.4.4.2.3. Radiation Therapy

11.4.4.2.4. Chemotherapy

11.4.4.2.5. Immunotherapy

11.4.4.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.4.2.5.2. Cytokine Treatment

11.4.4.2.5.3. Donor lymphocyte infusion

11.4.4.2.5.4. Monoclonal Antibody Treatment

11.4.4.2.5.5. Others

11.4.4.2.6. Targeted Therapy

11.4.4.2.7. Hormone Therapy

11.4.4.2.8. Stem Cell Therapy

11.4.4.2.8.1. Autologous stem cell transplantation

11.4.4.2.8.2. Allogeneic stem cell transplantation

11.4.4.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.4.2.8.4. Graft-Versus-Host Disease

11.4.4.2.9. Precision Medicine

11.4.4.2.10. Others

11.4.5. Italy

11.4.5.1. Italy Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.5.1.1. Breast Cancer

11.4.5.1.2. Prostate Cancer

11.4.5.1.3. Basal Cell Cancer

11.4.5.1.4. Skin Cancer (Non-Melanoma)

11.4.5.1.5. Colorectal cancer

11.4.5.1.6. Lung Cancer

11.4.5.1.7. Renal Cancer

11.4.5.1.8. Bladder Cancer

11.4.5.1.9. Lymphoma

11.4.5.1.10. Others

11.4.5.2. Italy Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.5.2.1. Drug Therapies

11.4.5.2.1.1. Antimetabolites

11.4.5.2.1.2. Antitumor Antibiotics

11.4.5.2.1.3. Asparagine-Specific Enzymes

11.4.5.2.1.4. Bisphosphonates and Biosimilars

11.4.5.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.5.2.1.6. Inhibitors

11.4.5.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.5.2.1.6.2. Histone Deacetylase Inhibitors

11.4.5.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.5.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.5.2.1.6.5. Proteasome Inhibitors

11.4.5.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.5.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.5.2.1.6.8. Others

11.4.5.2.1.7. Monoclonal Antibodies

11.4.5.2.1.8. Others

11.4.5.2.2. Surgery

11.4.5.2.2.1. Open Surgery

11.4.5.2.2.2. Minimally Invasive Surgery

11.4.5.2.3. Radiation Therapy

11.4.5.2.4. Chemotherapy

11.4.5.2.5. Immunotherapy

11.4.5.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.5.2.5.2. Cytokine Treatment

11.4.5.2.5.3. Donor lymphocyte infusion

11.4.5.2.5.4. Monoclonal Antibody Treatment

11.4.5.2.5.5. Others

11.4.5.2.6. Targeted Therapy

11.4.5.2.7. Hormone Therapy

11.4.5.2.8. Stem Cell Therapy

11.4.5.2.8.1. Autologous stem cell transplantation

11.4.5.2.8.2. Allogeneic stem cell transplantation

11.4.5.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.5.2.8.4. Graft-Versus-Host Disease

11.4.5.2.9. Precision Medicine

11.4.5.2.10. Others

11.4.6. Nordic Countries

11.4.6.1. Nordic Countries Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.6.1.1. Breast Cancer

11.4.6.1.2. Prostate Cancer

11.4.6.1.3. Basal Cell Cancer

11.4.6.1.4. Skin Cancer (Non-Melanoma)

11.4.6.1.5. Colorectal cancer

11.4.6.1.6. Lung Cancer

11.4.6.1.7. Renal Cancer

11.4.6.1.8. Bladder Cancer

11.4.6.1.9. Lymphoma

11.4.6.1.10. Others

11.4.6.2. Nordic Countries Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.6.2.1. Drug Therapies

11.4.6.2.1.1. Antimetabolites

11.4.6.2.1.2. Antitumor Antibiotics

11.4.6.2.1.3. Asparagine-Specific Enzymes

11.4.6.2.1.4. Bisphosphonates and Biosimilars

11.4.6.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.6.2.1.6. Inhibitors

11.4.6.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.6.2.1.6.2. Histone Deacetylase Inhibitors

11.4.6.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.6.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.6.2.1.6.5. Proteasome Inhibitors

11.4.6.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.6.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.6.2.1.6.8. Others

11.4.6.2.1.7. Monoclonal Antibodies

11.4.6.2.1.8. Others

11.4.6.2.2. Surgery

11.4.6.2.2.1. Open Surgery

11.4.6.2.2.2. Minimally Invasive Surgery

11.4.6.2.3. Radiation Therapy

11.4.6.2.4. Chemotherapy

11.4.6.2.5. Immunotherapy

11.4.6.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.6.2.5.2. Cytokine Treatment

11.4.6.2.5.3. Donor lymphocyte infusion

11.4.6.2.5.4. Monoclonal Antibody Treatment

11.4.6.2.5.5. Others

11.4.6.2.6. Targeted Therapy

11.4.6.2.7. Hormone Therapy

11.4.6.2.8. Stem Cell Therapy

11.4.6.2.8.1. Autologous stem cell transplantation

11.4.6.2.8.2. Allogeneic stem cell transplantation

11.4.6.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.6.2.8.4. Graft-Versus-Host Disease

11.4.6.2.9. Precision Medicine

11.4.6.2.10. Others

11.4.6.3. Nordic Countries Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.6.3.1. Denmark

11.4.6.3.2. Finland

11.4.6.3.3. Iceland

11.4.6.3.4. Sweden

11.4.6.3.5. Norway

11.4.7. Benelux Union

11.4.7.1. Benelux Union Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.7.1.1. Breast Cancer

11.4.7.1.2. Prostate Cancer

11.4.7.1.3. Basal Cell Cancer

11.4.7.1.4. Skin Cancer (Non-Melanoma)

11.4.7.1.5. Colorectal cancer

11.4.7.1.6. Lung Cancer

11.4.7.1.7. Renal Cancer

11.4.7.1.8. Bladder Cancer

11.4.7.1.9. Lymphoma

11.4.7.1.10. Others

11.4.7.2. Benelux Union Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.7.2.1. Drug Therapies

11.4.7.2.1.1. Antimetabolites

11.4.7.2.1.2. Antitumor Antibiotics

11.4.7.2.1.3. Asparagine-Specific Enzymes

11.4.7.2.1.4. Bisphosphonates and Biosimilars

11.4.7.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.7.2.1.6. Inhibitors

11.4.7.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.7.2.1.6.2. Histone Deacetylase Inhibitors

11.4.7.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.7.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.7.2.1.6.5. Proteasome Inhibitors

11.4.7.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.7.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.7.2.1.6.8. Others

11.4.7.2.1.7. Monoclonal Antibodies

11.4.7.2.1.8. Others

11.4.7.2.2. Surgery

11.4.7.2.2.1. Open Surgery

11.4.7.2.2.2. Minimally Invasive Surgery

11.4.7.2.3. Radiation Therapy

11.4.7.2.4. Chemotherapy

11.4.7.2.5. Immunotherapy

11.4.7.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.7.2.5.2. Cytokine Treatment

11.4.7.2.5.3. Donor lymphocyte infusion

11.4.7.2.5.4. Monoclonal Antibody Treatment

11.4.7.2.5.5. Others

11.4.7.2.6. Targeted Therapy

11.4.7.2.7. Hormone Therapy

11.4.7.2.8. Stem Cell Therapy

11.4.7.2.8.1. Autologous stem cell transplantation

11.4.7.2.8.2. Allogeneic stem cell transplantation

11.4.7.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.7.2.8.4. Graft-Versus-Host Disease

11.4.7.2.9. Precision Medicine

11.4.7.2.10. Others

11.4.7.3. Benelux Union Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.7.3.1. Belgium

11.4.7.3.2. The Netherlands

11.4.7.3.3. Luxembourg

11.4.8. Rest of Europe

11.4.8.1. Rest of Europe Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

11.4.8.1.1. Breast Cancer

11.4.8.1.2. Prostate Cancer

11.4.8.1.3. Basal Cell Cancer

11.4.8.1.4. Skin Cancer (Non-Melanoma)

11.4.8.1.5. Colorectal cancer

11.4.8.1.6. Lung Cancer

11.4.8.1.7. Renal Cancer

11.4.8.1.8. Bladder Cancer

11.4.8.1.9. Lymphoma

11.4.8.1.10. Others

11.4.8.2. Rest of Europe Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

11.4.8.2.1. Drug Therapies

11.4.8.2.1.1. Antimetabolites

11.4.8.2.1.2. Antitumor Antibiotics

11.4.8.2.1.3. Asparagine-Specific Enzymes

11.4.8.2.1.4. Bisphosphonates and Biosimilars

11.4.8.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

11.4.8.2.1.6. Inhibitors

11.4.8.2.1.6.1. DNA-Repair Enzyme Inhibitors

11.4.8.2.1.6.2. Histone Deacetylase Inhibitors

11.4.8.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

11.4.8.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

11.4.8.2.1.6.5. Proteasome Inhibitors

11.4.8.2.1.6.6. Tyrosine Kinase Inhibitors

11.4.8.2.1.6.7. PD-1 and PD-L1 inhibitors

11.4.8.2.1.6.8. Others

11.4.8.2.1.7. Monoclonal Antibodies

11.4.8.2.1.8. Others

11.4.8.2.2. Surgery

11.4.8.2.2.1. Open Surgery

11.4.8.2.2.2. Minimally Invasive Surgery

11.4.8.2.3. Radiation Therapy

11.4.8.2.4. Chemotherapy

11.4.8.2.5. Immunotherapy

11.4.8.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

11.4.8.2.5.2. Cytokine Treatment

11.4.8.2.5.3. Donor lymphocyte infusion

11.4.8.2.5.4. Monoclonal Antibody Treatment

11.4.8.2.5.5. Others

11.4.8.2.6. Targeted Therapy

11.4.8.2.7. Hormone Therapy

11.4.8.2.8. Stem Cell Therapy

11.4.8.2.8.1. Autologous stem cell transplantation

11.4.8.2.8.2. Allogeneic stem cell transplantation

11.4.8.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

11.4.8.2.8.4. Graft-Versus-Host Disease

11.4.8.2.9. Precision Medicine

11.4.8.2.10. Others

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Indication

11.5.3. By Treatment

12. Asia Pacific Oncology Drugs Market Analysis and Forecasts, 2019 - 2027

12.1. Overview

12.1.1. Asia Pacific Oncology Drugs Market Revenue (US$ Mn)

12.2. Asia Pacific Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.2.1. Breast Cancer

12.2.2. Prostate Cancer

12.2.3. Basal Cell Cancer

12.2.4. Skin Cancer (Non-Melanoma)

12.2.5. Colorectal cancer

12.2.6. Lung Cancer

12.2.7. Renal Cancer

12.2.8. Bladder Cancer

12.2.9. Lymphoma

12.2.10. Others

12.3. Asia Pacific Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.3.1. Drug Therapies

12.3.1.1. Antimetabolites

12.3.1.2. Antitumor Antibiotics

12.3.1.3. Asparagine-Specific Enzymes

12.3.1.4. Bisphosphonates and Biosimilars

12.3.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.3.1.6. Inhibitors

12.3.1.6.1. DNA-Repair Enzyme Inhibitors

12.3.1.6.2. Histone Deacetylase Inhibitors

12.3.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.3.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.3.1.6.5. Proteasome Inhibitors

12.3.1.6.6. Tyrosine Kinase Inhibitors

12.3.1.6.7. PD-1 and PD-L1 inhibitors

12.3.1.6.8. Others

12.3.1.7. Monoclonal Antibodies

12.3.1.8. Others

12.3.2. Surgery

12.3.2.1. Open Surgery

12.3.2.2. Minimally Invasive Surgery

12.3.3. Radiation Therapy

12.3.4. Chemotherapy

12.3.5. Immunotherapy

12.3.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.3.5.2. Cytokine Treatment

12.3.5.3. Donor lymphocyte infusion

12.3.5.4. Monoclonal Antibody Treatment

12.3.5.5. Others

12.3.6. Targeted Therapy

12.3.7. Hormone Therapy

12.3.8. Stem Cell Therapy

12.3.8.1. Autologous stem cell transplantation

12.3.8.2. Allogeneic stem cell transplantation

12.3.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.3.8.4. Graft-Versus-Host Disease

12.3.9. Precision Medicine

12.3.10. Others

12.4. Asia Pacific Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

12.4.1. China

12.4.1.1. China Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.1.1.1. Breast Cancer

12.4.1.1.2. Prostate Cancer

12.4.1.1.3. Basal Cell Cancer

12.4.1.1.4. Skin Cancer (Non-Melanoma)

12.4.1.1.5. Colorectal cancer

12.4.1.1.6. Lung Cancer

12.4.1.1.7. Renal Cancer

12.4.1.1.8. Bladder Cancer

12.4.1.1.9. Lymphoma

12.4.1.1.10. Others

12.4.1.2. China Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.1.2.1. Drug Therapies

12.4.1.2.1.1. Antimetabolites

12.4.1.2.1.2. Antitumor Antibiotics

12.4.1.2.1.3. Asparagine-Specific Enzymes

12.4.1.2.1.4. Bisphosphonates and Biosimilars

12.4.1.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.1.2.1.6. Inhibitors

12.4.1.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.1.2.1.6.2. Histone Deacetylase Inhibitors

12.4.1.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.1.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.1.2.1.6.5. Proteasome Inhibitors

12.4.1.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.1.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.1.2.1.6.8. Others

12.4.1.2.1.7. Monoclonal Antibodies

12.4.1.2.1.8. Others

12.4.1.2.2. Surgery

12.4.1.2.2.1. Open Surgery

12.4.1.2.2.2. Minimally Invasive Surgery

12.4.1.2.3. Radiation Therapy

12.4.1.2.4. Chemotherapy

12.4.1.2.5. Immunotherapy

12.4.1.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.1.2.5.2. Cytokine Treatment

12.4.1.2.5.3. Donor lymphocyte infusion

12.4.1.2.5.4. Monoclonal Antibody Treatment

12.4.1.2.5.5. Others

12.4.1.2.6. Targeted Therapy

12.4.1.2.7. Hormone Therapy

12.4.1.2.8. Stem Cell Therapy

12.4.1.2.8.1. Autologous stem cell transplantation

12.4.1.2.8.2. Allogeneic stem cell transplantation

12.4.1.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.1.2.8.4. Graft-Versus-Host Disease

12.4.1.2.9. Precision Medicine

12.4.1.2.10. Others

12.4.2. Japan

12.4.2.1. Japan Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.2.1.1. Breast Cancer

12.4.2.1.2. Prostate Cancer

12.4.2.1.3. Basal Cell Cancer

12.4.2.1.4. Skin Cancer (Non-Melanoma)

12.4.2.1.5. Colorectal cancer

12.4.2.1.6. Lung Cancer

12.4.2.1.7. Renal Cancer

12.4.2.1.8. Bladder Cancer

12.4.2.1.9. Lymphoma

12.4.2.1.10. Others

12.4.2.2. Japan Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.2.2.1. Drug Therapies

12.4.2.2.1.1. Antimetabolites

12.4.2.2.1.2. Antitumor Antibiotics

12.4.2.2.1.3. Asparagine-Specific Enzymes

12.4.2.2.1.4. Bisphosphonates and Biosimilars

12.4.2.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.2.2.1.6. Inhibitors

12.4.2.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.2.2.1.6.2. Histone Deacetylase Inhibitors

12.4.2.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.2.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.2.2.1.6.5. Proteasome Inhibitors

12.4.2.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.2.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.2.2.1.6.8. Others

12.4.2.2.1.7. Monoclonal Antibodies

12.4.2.2.1.8. Others

12.4.2.2.2. Surgery

12.4.2.2.2.1. Open Surgery

12.4.2.2.2.2. Minimally Invasive Surgery

12.4.2.2.3. Radiation Therapy

12.4.2.2.4. Chemotherapy

12.4.2.2.5. Immunotherapy

12.4.2.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.2.2.5.2. Cytokine Treatment

12.4.2.2.5.3. Donor lymphocyte infusion

12.4.2.2.5.4. Monoclonal Antibody Treatment

12.4.2.2.5.5. Others

12.4.2.2.6. Targeted Therapy

12.4.2.2.7. Hormone Therapy

12.4.2.2.8. Stem Cell Therapy

12.4.2.2.8.1. Autologous stem cell transplantation

12.4.2.2.8.2. Allogeneic stem cell transplantation

12.4.2.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.2.2.8.4. Graft-Versus-Host Disease

12.4.2.2.9. Precision Medicine

12.4.2.2.10. Others

12.4.3. India

12.4.3.1. India Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.3.1.1. Breast Cancer

12.4.3.1.2. Prostate Cancer

12.4.3.1.3. Basal Cell Cancer

12.4.3.1.4. Skin Cancer (Non-Melanoma)

12.4.3.1.5. Colorectal cancer

12.4.3.1.6. Lung Cancer

12.4.3.1.7. Renal Cancer

12.4.3.1.8. Bladder Cancer

12.4.3.1.9. Lymphoma

12.4.3.1.10. Others

12.4.3.2. India Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.3.2.1. Drug Therapies

12.4.3.2.1.1. Antimetabolites

12.4.3.2.1.2. Antitumor Antibiotics

12.4.3.2.1.3. Asparagine-Specific Enzymes

12.4.3.2.1.4. Bisphosphonates and Biosimilars

12.4.3.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.3.2.1.6. Inhibitors

12.4.3.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.3.2.1.6.2. Histone Deacetylase Inhibitors

12.4.3.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.3.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.3.2.1.6.5. Proteasome Inhibitors

12.4.3.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.3.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.3.2.1.6.8. Others

12.4.3.2.1.7. Monoclonal Antibodies

12.4.3.2.1.8. Others

12.4.3.2.2. Surgery

12.4.3.2.2.1. Open Surgery

12.4.3.2.2.2. Minimally Invasive Surgery

12.4.3.2.3. Radiation Therapy

12.4.3.2.4. Chemotherapy

12.4.3.2.5. Immunotherapy

12.4.3.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.3.2.5.2. Cytokine Treatment

12.4.3.2.5.3. Donor lymphocyte infusion

12.4.3.2.5.4. Monoclonal Antibody Treatment

12.4.3.2.5.5. Others

12.4.3.2.6. Targeted Therapy

12.4.3.2.7. Hormone Therapy

12.4.3.2.8. Stem Cell Therapy

12.4.3.2.8.1. Autologous stem cell transplantation

12.4.3.2.8.2. Allogeneic stem cell transplantation

12.4.3.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.3.2.8.4. Graft-Versus-Host Disease

12.4.3.2.9. Precision Medicine

12.4.3.2.10. Others

12.4.4. New Zealand

12.4.4.1. New Zealand Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.4.1.1. Breast Cancer

12.4.4.1.2. Prostate Cancer

12.4.4.1.3. Basal Cell Cancer

12.4.4.1.4. Skin Cancer (Non-Melanoma)

12.4.4.1.5. Colorectal cancer

12.4.4.1.6. Lung Cancer

12.4.4.1.7. Renal Cancer

12.4.4.1.8. Bladder Cancer

12.4.4.1.9. Lymphoma

12.4.4.1.10. Others

12.4.4.2. New Zealand Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.4.2.1. Drug Therapies

12.4.4.2.1.1. Antimetabolites

12.4.4.2.1.2. Antitumor Antibiotics

12.4.4.2.1.3. Asparagine-Specific Enzymes

12.4.4.2.1.4. Bisphosphonates and Biosimilars

12.4.4.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.4.2.1.6. Inhibitors

12.4.4.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.4.2.1.6.2. Histone Deacetylase Inhibitors

12.4.4.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.4.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.4.2.1.6.5. Proteasome Inhibitors

12.4.4.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.4.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.4.2.1.6.8. Others

12.4.4.2.1.7. Monoclonal Antibodies

12.4.4.2.1.8. Others

12.4.4.2.2. Surgery

12.4.4.2.2.1. Open Surgery

12.4.4.2.2.2. Minimally Invasive Surgery

12.4.4.2.3. Radiation Therapy

12.4.4.2.4. Chemotherapy

12.4.4.2.5. Immunotherapy

12.4.4.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.4.2.5.2. Cytokine Treatment

12.4.4.2.5.3. Donor lymphocyte infusion

12.4.4.2.5.4. Monoclonal Antibody Treatment

12.4.4.2.5.5. Others

12.4.4.2.6. Targeted Therapy

12.4.4.2.7. Hormone Therapy

12.4.4.2.8. Stem Cell Therapy

12.4.4.2.8.1. Autologous stem cell transplantation

12.4.4.2.8.2. Allogeneic stem cell transplantation

12.4.4.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.4.2.8.4. Graft-Versus-Host Disease

12.4.4.2.9. Precision Medicine

12.4.4.2.10. Others

12.4.5. Australia

12.4.5.1. Australia Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.5.1.1. Breast Cancer

12.4.5.1.2. Prostate Cancer

12.4.5.1.3. Basal Cell Cancer

12.4.5.1.4. Skin Cancer (Non-Melanoma)

12.4.5.1.5. Colorectal cancer

12.4.5.1.6. Lung Cancer

12.4.5.1.7. Renal Cancer

12.4.5.1.8. Bladder Cancer

12.4.5.1.9. Lymphoma

12.4.5.1.10. Others

12.4.5.2. Australia Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.5.2.1. Drug Therapies

12.4.5.2.1.1. Antimetabolites

12.4.5.2.1.2. Antitumor Antibiotics

12.4.5.2.1.3. Asparagine-Specific Enzymes

12.4.5.2.1.4. Bisphosphonates and Biosimilars

12.4.5.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.5.2.1.6. Inhibitors

12.4.5.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.5.2.1.6.2. Histone Deacetylase Inhibitors

12.4.5.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.5.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.5.2.1.6.5. Proteasome Inhibitors

12.4.5.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.5.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.5.2.1.6.8. Others

12.4.5.2.1.7. Monoclonal Antibodies

12.4.5.2.1.8. Others

12.4.5.2.2. Surgery

12.4.5.2.2.1. Open Surgery

12.4.5.2.2.2. Minimally Invasive Surgery

12.4.5.2.3. Radiation Therapy

12.4.5.2.4. Chemotherapy

12.4.5.2.5. Immunotherapy

12.4.5.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.5.2.5.2. Cytokine Treatment

12.4.5.2.5.3. Donor lymphocyte infusion

12.4.5.2.5.4. Monoclonal Antibody Treatment

12.4.5.2.5.5. Others

12.4.5.2.6. Targeted Therapy

12.4.5.2.7. Hormone Therapy

12.4.5.2.8. Stem Cell Therapy

12.4.5.2.8.1. Autologous stem cell transplantation

12.4.5.2.8.2. Allogeneic stem cell transplantation

12.4.5.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.5.2.8.4. Graft-Versus-Host Disease

12.4.5.2.9. Precision Medicine

12.4.5.2.10. Others

12.4.6. South Korea

12.4.6.1. South Korea Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.6.1.1. Breast Cancer

12.4.6.1.2. Prostate Cancer

12.4.6.1.3. Basal Cell Cancer

12.4.6.1.4. Skin Cancer (Non-Melanoma)

12.4.6.1.5. Colorectal cancer

12.4.6.1.6. Lung Cancer

12.4.6.1.7. Renal Cancer

12.4.6.1.8. Bladder Cancer

12.4.6.1.9. Lymphoma

12.4.6.1.10. Others

12.4.6.2. South Korea Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.6.2.1. Drug Therapies

12.4.6.2.1.1. Antimetabolites

12.4.6.2.1.2. Antitumor Antibiotics

12.4.6.2.1.3. Asparagine-Specific Enzymes

12.4.6.2.1.4. Bisphosphonates and Biosimilars

12.4.6.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.6.2.1.6. Inhibitors

12.4.6.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.6.2.1.6.2. Histone Deacetylase Inhibitors

12.4.6.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.6.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.6.2.1.6.5. Proteasome Inhibitors

12.4.6.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.6.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.6.2.1.6.8. Others

12.4.6.2.1.7. Monoclonal Antibodies

12.4.6.2.1.8. Others

12.4.6.2.2. Surgery

12.4.6.2.2.1. Open Surgery

12.4.6.2.2.2. Minimally Invasive Surgery

12.4.6.2.3. Radiation Therapy

12.4.6.2.4. Chemotherapy

12.4.6.2.5. Immunotherapy

12.4.6.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.6.2.5.2. Cytokine Treatment

12.4.6.2.5.3. Donor lymphocyte infusion

12.4.6.2.5.4. Monoclonal Antibody Treatment

12.4.6.2.5.5. Others

12.4.6.2.6. Targeted Therapy

12.4.6.2.7. Hormone Therapy

12.4.6.2.8. Stem Cell Therapy

12.4.6.2.8.1. Autologous stem cell transplantation

12.4.6.2.8.2. Allogeneic stem cell transplantation

12.4.6.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.6.2.8.4. Graft-Versus-Host Disease

12.4.6.2.9. Precision Medicine

12.4.6.2.10. Others

12.4.7. Southeast Asia

12.4.7.1. Southeast Asia Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.7.1.1. Breast Cancer

12.4.7.1.2. Prostate Cancer

12.4.7.1.3. Basal Cell Cancer

12.4.7.1.4. Skin Cancer (Non-Melanoma)

12.4.7.1.5. Colorectal cancer

12.4.7.1.6. Lung Cancer

12.4.7.1.7. Renal Cancer

12.4.7.1.8. Bladder Cancer

12.4.7.1.9. Lymphoma

12.4.7.1.10. Others

12.4.7.2. Southeast Asia Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.7.2.1. Drug Therapies

12.4.7.2.1.1. Antimetabolites

12.4.7.2.1.2. Antitumor Antibiotics

12.4.7.2.1.3. Asparagine-Specific Enzymes

12.4.7.2.1.4. Bisphosphonates and Biosimilars

12.4.7.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.7.2.1.6. Inhibitors

12.4.7.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.7.2.1.6.2. Histone Deacetylase Inhibitors

12.4.7.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.7.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.7.2.1.6.5. Proteasome Inhibitors

12.4.7.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.7.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.7.2.1.6.8. Others

12.4.7.2.1.7. Monoclonal Antibodies

12.4.7.2.1.8. Others

12.4.7.2.2. Surgery

12.4.7.2.2.1. Open Surgery

12.4.7.2.2.2. Minimally Invasive Surgery

12.4.7.2.3. Radiation Therapy

12.4.7.2.4. Chemotherapy

12.4.7.2.5. Immunotherapy

12.4.7.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.7.2.5.2. Cytokine Treatment

12.4.7.2.5.3. Donor lymphocyte infusion

12.4.7.2.5.4. Monoclonal Antibody Treatment

12.4.7.2.5.5. Others

12.4.7.2.6. Targeted Therapy

12.4.7.2.7. Hormone Therapy

12.4.7.2.8. Stem Cell Therapy

12.4.7.2.8.1. Autologous stem cell transplantation

12.4.7.2.8.2. Allogeneic stem cell transplantation

12.4.7.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.7.2.8.4. Graft-Versus-Host Disease

12.4.7.2.9. Precision Medicine

12.4.7.2.10. Others

12.4.7.3. Southeast Asia Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

12.4.7.3.1. Indonesia

12.4.7.3.2. Thailand

12.4.7.3.3. Malaysia

12.4.7.3.4. Singapore

12.4.7.3.5. Rest of Southeast Asia

12.4.8. Rest of Asia Pacific

12.4.8.1. Rest of Asia Pacific Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

12.4.8.1.1. Breast Cancer

12.4.8.1.2. Prostate Cancer

12.4.8.1.3. Basal Cell Cancer

12.4.8.1.4. Skin Cancer (Non-Melanoma)

12.4.8.1.5. Colorectal cancer

12.4.8.1.6. Lung Cancer

12.4.8.1.7. Renal Cancer

12.4.8.1.8. Bladder Cancer

12.4.8.1.9. Lymphoma

12.4.8.1.10. Others

12.4.8.2. Rest of Asia Pacific Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

12.4.8.2.1. Drug Therapies

12.4.8.2.1.1. Antimetabolites

12.4.8.2.1.2. Antitumor Antibiotics

12.4.8.2.1.3. Asparagine-Specific Enzymes

12.4.8.2.1.4. Bisphosphonates and Biosimilars

12.4.8.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

12.4.8.2.1.6. Inhibitors

12.4.8.2.1.6.1. DNA-Repair Enzyme Inhibitors

12.4.8.2.1.6.2. Histone Deacetylase Inhibitors

12.4.8.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

12.4.8.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

12.4.8.2.1.6.5. Proteasome Inhibitors

12.4.8.2.1.6.6. Tyrosine Kinase Inhibitors

12.4.8.2.1.6.7. PD-1 and PD-L1 inhibitors

12.4.8.2.1.6.8. Others

12.4.8.2.1.7. Monoclonal Antibodies

12.4.8.2.1.8. Others

12.4.8.2.2. Surgery

12.4.8.2.2.1. Open Surgery

12.4.8.2.2.2. Minimally Invasive Surgery

12.4.8.2.3. Radiation Therapy

12.4.8.2.4. Chemotherapy

12.4.8.2.5. Immunotherapy

12.4.8.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

12.4.8.2.5.2. Cytokine Treatment

12.4.8.2.5.3. Donor lymphocyte infusion

12.4.8.2.5.4. Monoclonal Antibody Treatment

12.4.8.2.5.5. Others

12.4.8.2.6. Targeted Therapy

12.4.8.2.7. Hormone Therapy

12.4.8.2.8. Stem Cell Therapy

12.4.8.2.8.1. Autologous stem cell transplantation

12.4.8.2.8.2. Allogeneic stem cell transplantation

12.4.8.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

12.4.8.2.8.4. Graft-Versus-Host Disease

12.4.8.2.9. Precision Medicine

12.4.8.2.10. Others

12.5. Key Segment for Channeling Investments

12.5.1. By Country

12.5.2. By Indication

12.5.3. By Treatment

13. Middle East and Africa Oncology Drugs Market Analysis and Forecasts, 2019 - 2027

13.1. Overview

13.1.1. Middle East and Africa Oncology Drugs Market Revenue (US$ Mn)

13.2. Middle East and Africa Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

13.2.1. Breast Cancer

13.2.2. Prostate Cancer

13.2.3. Basal Cell Cancer

13.2.4. Skin Cancer (Non-Melanoma)

13.2.5. Colorectal cancer

13.2.6. Lung Cancer

13.2.7. Renal Cancer

13.2.8. Bladder Cancer

13.2.9. Lymphoma

13.2.10. Others

13.3. Middle East and Africa Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

13.3.1. Drug Therapies

13.3.1.1. Antimetabolites

13.3.1.2. Antitumor Antibiotics

13.3.1.3. Asparagine-Specific Enzymes

13.3.1.4. Bisphosphonates and Biosimilars

13.3.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

13.3.1.6. Inhibitors

13.3.1.6.1. DNA-Repair Enzyme Inhibitors

13.3.1.6.2. Histone Deacetylase Inhibitors

13.3.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

13.3.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

13.3.1.6.5. Proteasome Inhibitors

13.3.1.6.6. Tyrosine Kinase Inhibitors

13.3.1.6.7. PD-1 and PD-L1 inhibitors

13.3.1.6.8. Others

13.3.1.7. Monoclonal Antibodies

13.3.1.8. Others

13.3.2. Surgery

13.3.2.1. Open Surgery

13.3.2.2. Minimally Invasive Surgery

13.3.3. Radiation Therapy

13.3.4. Chemotherapy

13.3.5. Immunotherapy

13.3.5.1. Chimeric antigen receptor (CAR) T-cell therapy

13.3.5.2. Cytokine Treatment

13.3.5.3. Donor lymphocyte infusion

13.3.5.4. Monoclonal Antibody Treatment

13.3.5.5. Others

13.3.6. Targeted Therapy

13.3.7. Hormone Therapy

13.3.8. Stem Cell Therapy

13.3.8.1. Autologous stem cell transplantation

13.3.8.2. Allogeneic stem cell transplantation

13.3.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

13.3.8.4. Graft-Versus-Host Disease

13.3.9. Precision Medicine

13.3.10. Others

13.4. Middle East and Africa Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

13.4.1. Saudi Arabia

13.4.1.1. Saudi Arabia Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

13.4.1.1.1. Breast Cancer

13.4.1.1.2. Prostate Cancer

13.4.1.1.3. Basal Cell Cancer

13.4.1.1.4. Skin Cancer (Non-Melanoma)

13.4.1.1.5. Colorectal cancer

13.4.1.1.6. Lung Cancer

13.4.1.1.7. Renal Cancer

13.4.1.1.8. Bladder Cancer

13.4.1.1.9. Lymphoma

13.4.1.1.10. Others

13.4.1.2. Saudi Arabia Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

13.4.1.2.1. Drug Therapies

13.4.1.2.1.1. Antimetabolites

13.4.1.2.1.2. Antitumor Antibiotics

13.4.1.2.1.3. Asparagine-Specific Enzymes

13.4.1.2.1.4. Bisphosphonates and Biosimilars

13.4.1.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

13.4.1.2.1.6. Inhibitors

13.4.1.2.1.6.1. DNA-Repair Enzyme Inhibitors

13.4.1.2.1.6.2. Histone Deacetylase Inhibitors

13.4.1.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

13.4.1.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

13.4.1.2.1.6.5. Proteasome Inhibitors

13.4.1.2.1.6.6. Tyrosine Kinase Inhibitors

13.4.1.2.1.6.7. PD-1 and PD-L1 inhibitors

13.4.1.2.1.6.8. Others

13.4.1.2.1.7. Monoclonal Antibodies

13.4.1.2.1.8. Others

13.4.1.2.2. Surgery

13.4.1.2.2.1. Open Surgery

13.4.1.2.2.2. Minimally Invasive Surgery

13.4.1.2.3. Radiation Therapy

13.4.1.2.4. Chemotherapy

13.4.1.2.5. Immunotherapy

13.4.1.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

13.4.1.2.5.2. Cytokine Treatment

13.4.1.2.5.3. Donor lymphocyte infusion

13.4.1.2.5.4. Monoclonal Antibody Treatment

13.4.1.2.5.5. Others

13.4.1.2.6. Targeted Therapy

13.4.1.2.7. Hormone Therapy

13.4.1.2.8. Stem Cell Therapy

13.4.1.2.8.1. Autologous stem cell transplantation

13.4.1.2.8.2. Allogeneic stem cell transplantation

13.4.1.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

13.4.1.2.8.4. Graft-Versus-Host Disease

13.4.1.2.9. Precision Medicine

13.4.1.2.10. Others

13.4.2. UAE

13.4.2.1. UAE Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

13.4.2.1.1. Breast Cancer

13.4.2.1.2. Prostate Cancer

13.4.2.1.3. Basal Cell Cancer

13.4.2.1.4. Skin Cancer (Non-Melanoma)

13.4.2.1.5. Colorectal cancer

13.4.2.1.6. Lung Cancer

13.4.2.1.7. Renal Cancer

13.4.2.1.8. Bladder Cancer

13.4.2.1.9. Lymphoma

13.4.2.1.10. Others

13.4.2.2. UAE Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

13.4.2.2.1. Drug Therapies

13.4.2.2.1.1. Antimetabolites

13.4.2.2.1.2. Antitumor Antibiotics

13.4.2.2.1.3. Asparagine-Specific Enzymes

13.4.2.2.1.4. Bisphosphonates and Biosimilars

13.4.2.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

13.4.2.2.1.6. Inhibitors

13.4.2.2.1.6.1. DNA-Repair Enzyme Inhibitors

13.4.2.2.1.6.2. Histone Deacetylase Inhibitors

13.4.2.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

13.4.2.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

13.4.2.2.1.6.5. Proteasome Inhibitors

13.4.2.2.1.6.6. Tyrosine Kinase Inhibitors

13.4.2.2.1.6.7. PD-1 and PD-L1 inhibitors

13.4.2.2.1.6.8. Others

13.4.2.2.1.7. Monoclonal Antibodies

13.4.2.2.1.8. Others

13.4.2.2.2. Surgery

13.4.2.2.2.1. Open Surgery

13.4.2.2.2.2. Minimally Invasive Surgery

13.4.2.2.3. Radiation Therapy

13.4.2.2.4. Chemotherapy

13.4.2.2.5. Immunotherapy

13.4.2.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

13.4.2.2.5.2. Cytokine Treatment

13.4.2.2.5.3. Donor lymphocyte infusion

13.4.2.2.5.4. Monoclonal Antibody Treatment

13.4.2.2.5.5. Others

13.4.2.2.6. Targeted Therapy

13.4.2.2.7. Hormone Therapy

13.4.2.2.8. Stem Cell Therapy

13.4.2.2.8.1. Autologous stem cell transplantation

13.4.2.2.8.2. Allogeneic stem cell transplantation

13.4.2.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

13.4.2.2.8.4. Graft-Versus-Host Disease

13.4.2.2.9. Precision Medicine

13.4.2.2.10. Others

13.4.3. Egypt

13.4.3.1. Egypt Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

13.4.3.1.1. Breast Cancer

13.4.3.1.2. Prostate Cancer

13.4.3.1.3. Basal Cell Cancer

13.4.3.1.4. Skin Cancer (Non-Melanoma)

13.4.3.1.5. Colorectal cancer

13.4.3.1.6. Lung Cancer

13.4.3.1.7. Renal Cancer

13.4.3.1.8. Bladder Cancer

13.4.3.1.9. Lymphoma

13.4.3.1.10. Others

13.4.3.2. Egypt Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

13.4.3.2.1. Drug Therapies

13.4.3.2.1.1. Antimetabolites

13.4.3.2.1.2. Antitumor Antibiotics

13.4.3.2.1.3. Asparagine-Specific Enzymes

13.4.3.2.1.4. Bisphosphonates and Biosimilars

13.4.3.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

13.4.3.2.1.6. Inhibitors

13.4.3.2.1.6.1. DNA-Repair Enzyme Inhibitors

13.4.3.2.1.6.2. Histone Deacetylase Inhibitors

13.4.3.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

13.4.3.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

13.4.3.2.1.6.5. Proteasome Inhibitors

13.4.3.2.1.6.6. Tyrosine Kinase Inhibitors

13.4.3.2.1.6.7. PD-1 and PD-L1 inhibitors

13.4.3.2.1.6.8. Others

13.4.3.2.1.7. Monoclonal Antibodies

13.4.3.2.1.8. Others

13.4.3.2.2. Surgery

13.4.3.2.2.1. Open Surgery

13.4.3.2.2.2. Minimally Invasive Surgery

13.4.3.2.3. Radiation Therapy

13.4.3.2.4. Chemotherapy

13.4.3.2.5. Immunotherapy

13.4.3.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

13.4.3.2.5.2. Cytokine Treatment

13.4.3.2.5.3. Donor lymphocyte infusion

13.4.3.2.5.4. Monoclonal Antibody Treatment

13.4.3.2.5.5. Others

13.4.3.2.6. Targeted Therapy

13.4.3.2.7. Hormone Therapy

13.4.3.2.8. Stem Cell Therapy

13.4.3.2.8.1. Autologous stem cell transplantation

13.4.3.2.8.2. Allogeneic stem cell transplantation

13.4.3.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

13.4.3.2.8.4. Graft-Versus-Host Disease

13.4.3.2.9. Precision Medicine

13.4.3.2.10. Others

13.4.4. Kuwait

13.4.4.1. Kuwait Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

13.4.4.1.1. Breast Cancer

13.4.4.1.2. Prostate Cancer

13.4.4.1.3. Basal Cell Cancer

13.4.4.1.4. Skin Cancer (Non-Melanoma)

13.4.4.1.5. Colorectal cancer

13.4.4.1.6. Lung Cancer

13.4.4.1.7. Renal Cancer

13.4.4.1.8. Bladder Cancer

13.4.4.1.9. Lymphoma

13.4.4.1.10. Others

13.4.4.2. Kuwait Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

13.4.4.2.1. Drug Therapies

13.4.4.2.1.1. Antimetabolites

13.4.4.2.1.2. Antitumor Antibiotics

13.4.4.2.1.3. Asparagine-Specific Enzymes

13.4.4.2.1.4. Bisphosphonates and Biosimilars

13.4.4.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

13.4.4.2.1.6. Inhibitors

13.4.4.2.1.6.1. DNA-Repair Enzyme Inhibitors

13.4.4.2.1.6.2. Histone Deacetylase Inhibitors

13.4.4.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

13.4.4.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

13.4.4.2.1.6.5. Proteasome Inhibitors

13.4.4.2.1.6.6. Tyrosine Kinase Inhibitors

13.4.4.2.1.6.7. PD-1 and PD-L1 inhibitors

13.4.4.2.1.6.8. Others

13.4.4.2.1.7. Monoclonal Antibodies

13.4.4.2.1.8. Others

13.4.4.2.2. Surgery

13.4.4.2.2.1. Open Surgery

13.4.4.2.2.2. Minimally Invasive Surgery

13.4.4.2.3. Radiation Therapy

13.4.4.2.4. Chemotherapy

13.4.4.2.5. Immunotherapy

13.4.4.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

13.4.4.2.5.2. Cytokine Treatment

13.4.4.2.5.3. Donor lymphocyte infusion

13.4.4.2.5.4. Monoclonal Antibody Treatment

13.4.4.2.5.5. Others

13.4.4.2.6. Targeted Therapy

13.4.4.2.7. Hormone Therapy

13.4.4.2.8. Stem Cell Therapy

13.4.4.2.8.1. Autologous stem cell transplantation

13.4.4.2.8.2. Allogeneic stem cell transplantation

13.4.4.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

13.4.4.2.8.4. Graft-Versus-Host Disease

13.4.4.2.9. Precision Medicine

13.4.4.2.10. Others

13.4.5. South Africa

13.4.5.1. South Africa Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

13.4.5.1.1. Breast Cancer

13.4.5.1.2. Prostate Cancer

13.4.5.1.3. Basal Cell Cancer

13.4.5.1.4. Skin Cancer (Non-Melanoma)

13.4.5.1.5. Colorectal cancer

13.4.5.1.6. Lung Cancer

13.4.5.1.7. Renal Cancer

13.4.5.1.8. Bladder Cancer

13.4.5.1.9. Lymphoma

13.4.5.1.10. Others

13.4.5.2. South Africa Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

13.4.5.2.1. Drug Therapies

13.4.5.2.1.1. Antimetabolites

13.4.5.2.1.2. Antitumor Antibiotics

13.4.5.2.1.3. Asparagine-Specific Enzymes

13.4.5.2.1.4. Bisphosphonates and Biosimilars

13.4.5.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

13.4.5.2.1.6. Inhibitors

13.4.5.2.1.6.1. DNA-Repair Enzyme Inhibitors

13.4.5.2.1.6.2. Histone Deacetylase Inhibitors

13.4.5.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

13.4.5.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

13.4.5.2.1.6.5. Proteasome Inhibitors

13.4.5.2.1.6.6. Tyrosine Kinase Inhibitors

13.4.5.2.1.6.7. PD-1 and PD-L1 inhibitors

13.4.5.2.1.6.8. Others

13.4.5.2.1.7. Monoclonal Antibodies

13.4.5.2.1.8. Others

13.4.5.2.2. Surgery

13.4.5.2.2.1. Open Surgery

13.4.5.2.2.2. Minimally Invasive Surgery

13.4.5.2.3. Radiation Therapy

13.4.5.2.4. Chemotherapy

13.4.5.2.5. Immunotherapy

13.4.5.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

13.4.5.2.5.2. Cytokine Treatment

13.4.5.2.5.3. Donor lymphocyte infusion

13.4.5.2.5.4. Monoclonal Antibody Treatment

13.4.5.2.5.5. Others

13.4.5.2.6. Targeted Therapy

13.4.5.2.7. Hormone Therapy

13.4.5.2.8. Stem Cell Therapy

13.4.5.2.8.1. Autologous stem cell transplantation

13.4.5.2.8.2. Allogeneic stem cell transplantation

13.4.5.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

13.4.5.2.8.4. Graft-Versus-Host Disease

13.4.5.2.9. Precision Medicine

13.4.5.2.10. Others

13.4.6. Rest of Middle East & Africa

13.4.6.1. Rest of Middle East & Africa Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

13.4.6.1.1. Breast Cancer

13.4.6.1.2. Prostate Cancer

13.4.6.1.3. Basal Cell Cancer

13.4.6.1.4. Skin Cancer (Non-Melanoma)

13.4.6.1.5. Colorectal cancer

13.4.6.1.6. Lung Cancer

13.4.6.1.7. Renal Cancer

13.4.6.1.8. Bladder Cancer

13.4.6.1.9. Lymphoma

13.4.6.1.10. Others

13.4.6.2. Rest of Middle East & Africa Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

13.4.6.2.1. Drug Therapies

13.4.6.2.1.1. Antimetabolites

13.4.6.2.1.2. Antitumor Antibiotics

13.4.6.2.1.3. Asparagine-Specific Enzymes

13.4.6.2.1.4. Bisphosphonates and Biosimilars

13.4.6.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

13.4.6.2.1.6. Inhibitors

13.4.6.2.1.6.1. DNA-Repair Enzyme Inhibitors

13.4.6.2.1.6.2. Histone Deacetylase Inhibitors

13.4.6.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

13.4.6.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

13.4.6.2.1.6.5. Proteasome Inhibitors

13.4.6.2.1.6.6. Tyrosine Kinase Inhibitors

13.4.6.2.1.6.7. PD-1 and PD-L1 inhibitors

13.4.6.2.1.6.8. Others

13.4.6.2.1.7. Monoclonal Antibodies

13.4.6.2.1.8. Others

13.4.6.2.2. Surgery

13.4.6.2.2.1. Open Surgery

13.4.6.2.2.2. Minimally Invasive Surgery

13.4.6.2.3. Radiation Therapy

13.4.6.2.4. Chemotherapy

13.4.6.2.5. Immunotherapy

13.4.6.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

13.4.6.2.5.2. Cytokine Treatment

13.4.6.2.5.3. Donor lymphocyte infusion

13.4.6.2.5.4. Monoclonal Antibody Treatment

13.4.6.2.5.5. Others

13.4.6.2.6. Targeted Therapy

13.4.6.2.7. Hormone Therapy

13.4.6.2.8. Stem Cell Therapy

13.4.6.2.8.1. Autologous stem cell transplantation

13.4.6.2.8.2. Allogeneic stem cell transplantation

13.4.6.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

13.4.6.2.8.4. Graft-Versus-Host Disease

13.4.6.2.9. Precision Medicine

13.4.6.2.10. Others

13.5. Key Segment for Channeling Investments

13.5.1. By Country

13.5.2. By Indication

13.5.3. By Treatment

14. Latin America Oncology Drugs Market Analysis and Forecasts, 2019 - 2027

14.1. Overview

14.1.1. Latin America Oncology Drugs Market Revenue (US$ Mn)

14.2. Latin America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

14.2.1. Breast Cancer

14.2.2. Prostate Cancer

14.2.3. Basal Cell Cancer

14.2.4. Skin Cancer (Non-Melanoma)

14.2.5. Colorectal cancer

14.2.6. Lung Cancer

14.2.7. Renal Cancer

14.2.8. Bladder Cancer

14.2.9. Lymphoma

14.2.10. Others

14.3. Latin America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

14.3.1. Drug Therapies

14.3.1.1. Antimetabolites

14.3.1.2. Antitumor Antibiotics

14.3.1.3. Asparagine-Specific Enzymes

14.3.1.4. Bisphosphonates and Biosimilars

14.3.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

14.3.1.6. Inhibitors

14.3.1.6.1. DNA-Repair Enzyme Inhibitors

14.3.1.6.2. Histone Deacetylase Inhibitors

14.3.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

14.3.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

14.3.1.6.5. Proteasome Inhibitors

14.3.1.6.6. Tyrosine Kinase Inhibitors

14.3.1.6.7. PD-1 and PD-L1 inhibitors

14.3.1.6.8. Others

14.3.1.7. Monoclonal Antibodies

14.3.1.8. Others

14.3.2. Surgery

14.3.2.1. Open Surgery

14.3.2.2. Minimally Invasive Surgery

14.3.3. Radiation Therapy

14.3.4. Chemotherapy

14.3.5. Immunotherapy

14.3.5.1. Chimeric antigen receptor (CAR) T-cell therapy

14.3.5.2. Cytokine Treatment

14.3.5.3. Donor lymphocyte infusion

14.3.5.4. Monoclonal Antibody Treatment

14.3.5.5. Others

14.3.6. Targeted Therapy

14.3.7. Hormone Therapy

14.3.8. Stem Cell Therapy

14.3.8.1. Autologous stem cell transplantation

14.3.8.2. Allogeneic stem cell transplantation

14.3.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

14.3.8.4. Graft-Versus-Host Disease

14.3.9. Precision Medicine

14.3.10. Others

14.4. Latin America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Country

14.4.1. Brazil

14.4.1.1. Brazil Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

14.4.1.1.1. Breast Cancer

14.4.1.1.2. Prostate Cancer

14.4.1.1.3. Basal Cell Cancer

14.4.1.1.4. Skin Cancer (Non-Melanoma)

14.4.1.1.5. Colorectal cancer

14.4.1.1.6. Lung Cancer

14.4.1.1.7. Renal Cancer

14.4.1.1.8. Bladder Cancer

14.4.1.1.9. Lymphoma

14.4.1.1.10. Others

14.4.1.2. Brazil Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

14.4.1.2.1. Drug Therapies

14.4.1.2.1.1. Antimetabolites

14.4.1.2.1.2. Antitumor Antibiotics

14.4.1.2.1.3. Asparagine-Specific Enzymes

14.4.1.2.1.4. Bisphosphonates and Biosimilars

14.4.1.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

14.4.1.2.1.6. Inhibitors

14.4.1.2.1.6.1. DNA-Repair Enzyme Inhibitors

14.4.1.2.1.6.2. Histone Deacetylase Inhibitors

14.4.1.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

14.4.1.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

14.4.1.2.1.6.5. Proteasome Inhibitors

14.4.1.2.1.6.6. Tyrosine Kinase Inhibitors

14.4.1.2.1.6.7. PD-1 and PD-L1 inhibitors

14.4.1.2.1.6.8. Others

14.4.1.2.1.7. Monoclonal Antibodies

14.4.1.2.1.8. Others

14.4.1.2.2. Surgery

14.4.1.2.2.1. Open Surgery

14.4.1.2.2.2. Minimally Invasive Surgery

14.4.1.2.3. Radiation Therapy

14.4.1.2.4. Chemotherapy

14.4.1.2.5. Immunotherapy

14.4.1.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

14.4.1.2.5.2. Cytokine Treatment

14.4.1.2.5.3. Donor lymphocyte infusion

14.4.1.2.5.4. Monoclonal Antibody Treatment

14.4.1.2.5.5. Others

14.4.1.2.6. Targeted Therapy

14.4.1.2.7. Hormone Therapy

14.4.1.2.8. Stem Cell Therapy

14.4.1.2.8.1. Autologous stem cell transplantation

14.4.1.2.8.2. Allogeneic stem cell transplantation

14.4.1.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

14.4.1.2.8.4. Graft-Versus-Host Disease

14.4.1.2.9. Precision Medicine

14.4.1.2.10. Others

14.4.2. Argentina

14.4.2.1. Argentina Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

14.4.2.1.1. Breast Cancer

14.4.2.1.2. Prostate Cancer

14.4.2.1.3. Basal Cell Cancer

14.4.2.1.4. Skin Cancer (Non-Melanoma)

14.4.2.1.5. Colorectal cancer

14.4.2.1.6. Lung Cancer

14.4.2.1.7. Renal Cancer

14.4.2.1.8. Bladder Cancer

14.4.2.1.9. Lymphoma

14.4.2.1.10. Others

14.4.2.2. Argentina Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

14.4.2.2.1. Drug Therapies

14.4.2.2.1.1. Antimetabolites

14.4.2.2.1.2. Antitumor Antibiotics

14.4.2.2.1.3. Asparagine-Specific Enzymes

14.4.2.2.1.4. Bisphosphonates and Biosimilars

14.4.2.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

14.4.2.2.1.6. Inhibitors

14.4.2.2.1.6.1. DNA-Repair Enzyme Inhibitors

14.4.2.2.1.6.2. Histone Deacetylase Inhibitors

14.4.2.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

14.4.2.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

14.4.2.2.1.6.5. Proteasome Inhibitors

14.4.2.2.1.6.6. Tyrosine Kinase Inhibitors

14.4.2.2.1.6.7. PD-1 and PD-L1 inhibitors

14.4.2.2.1.6.8. Others

14.4.2.2.1.7. Monoclonal Antibodies

14.4.2.2.1.8. Others

14.4.2.2.2. Surgery

14.4.2.2.2.1. Open Surgery

14.4.2.2.2.2. Minimally Invasive Surgery

14.4.2.2.3. Radiation Therapy

14.4.2.2.4. Chemotherapy

14.4.2.2.5. Immunotherapy

14.4.2.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

14.4.2.2.5.2. Cytokine Treatment

14.4.2.2.5.3. Donor lymphocyte infusion

14.4.2.2.5.4. Monoclonal Antibody Treatment

14.4.2.2.5.5. Others

14.4.2.2.6. Targeted Therapy

14.4.2.2.7. Hormone Therapy

14.4.2.2.8. Stem Cell Therapy

14.4.2.2.8.1. Autologous stem cell transplantation

14.4.2.2.8.2. Allogeneic stem cell transplantation

14.4.2.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

14.4.2.2.8.4. Graft-Versus-Host Disease

14.4.2.2.9. Precision Medicine

14.4.2.2.10. Others

14.4.3. Rest of Latin America

14.4.3.1. Rest of Latin America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Indication

14.4.3.1.1. Breast Cancer

14.4.3.1.2. Prostate Cancer

14.4.3.1.3. Basal Cell Cancer

14.4.3.1.4. Skin Cancer (Non-Melanoma)

14.4.3.1.5. Colorectal cancer

14.4.3.1.6. Lung Cancer

14.4.3.1.7. Renal Cancer

14.4.3.1.8. Bladder Cancer

14.4.3.1.9. Lymphoma

14.4.3.1.10. Others

14.4.3.2. Rest of Latin America Oncology Drugs Market Revenue (US$ Mn) and Forecasts, By Treatment

14.4.3.2.1. Drug Therapies

14.4.3.2.1.1. Antimetabolites

14.4.3.2.1.2. Antitumor Antibiotics

14.4.3.2.1.3. Asparagine-Specific Enzymes

14.4.3.2.1.4. Bisphosphonates and Biosimilars

14.4.3.2.1.5. DNA-Damaging Agents (Antineoplastics) and Alkylating Agents

14.4.3.2.1.6. Inhibitors

14.4.3.2.1.6.1. DNA-Repair Enzyme Inhibitors

14.4.3.2.1.6.2. Histone Deacetylase Inhibitors

14.4.3.2.1.6.3. Janus-Associated Kinase (JAK) Inhibitors

14.4.3.2.1.6.4. Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)

14.4.3.2.1.6.5. Proteasome Inhibitors

14.4.3.2.1.6.6. Tyrosine Kinase Inhibitors

14.4.3.2.1.6.7. PD-1 and PD-L1 inhibitors

14.4.3.2.1.6.8. Others

14.4.3.2.1.7. Monoclonal Antibodies

14.4.3.2.1.8. Others

14.4.3.2.2. Surgery

14.4.3.2.2.1. Open Surgery

14.4.3.2.2.2. Minimally Invasive Surgery

14.4.3.2.3. Radiation Therapy

14.4.3.2.4. Chemotherapy

14.4.3.2.5. Immunotherapy

14.4.3.2.5.1. Chimeric antigen receptor (CAR) T-cell therapy

14.4.3.2.5.2. Cytokine Treatment

14.4.3.2.5.3. Donor lymphocyte infusion

14.4.3.2.5.4. Monoclonal Antibody Treatment

14.4.3.2.5.5. Others

14.4.3.2.6. Targeted Therapy

14.4.3.2.7. Hormone Therapy

14.4.3.2.8. Stem Cell Therapy

14.4.3.2.8.1. Autologous stem cell transplantation

14.4.3.2.8.2. Allogeneic stem cell transplantation

14.4.3.2.8.3. Reduced-Intensity Allogeneic Stem Cell Transplantation

14.4.3.2.8.4. Graft-Versus-Host Disease

14.4.3.2.9. Precision Medicine

14.4.3.2.10. Others

14.5. Key Segment for Channeling Investments

14.5.1. By Country

14.5.2. By Indication

14.5.3. By Treatment

15. Competitive Benchmarking

15.1. Market Share Analysis, 2018

15.2. Global Presence and Growth Strategies

15.2.1. Mergers and Acquisitions

15.2.2. Product Launches

15.2.3. Investments Trends

15.2.4. R&D Initiatives

16. Player Profiles

16.1. AstraZeneca

16.1.1. Company Details

16.1.2. Company Overview

16.1.3. Product Offerings

16.1.4. Key Developments

16.1.5. Financial Analysis

16.1.6. SWOT Analysis

16.1.7. Business Strategies

16.2. Bayer Ag

16.2.1. Company Details

16.2.2. Company Overview

16.2.3. Product Offerings

16.2.4. Key Developments

16.2.5. Financial Analysis

16.2.6. SWOT Analysis

16.2.7. Business Strategies

16.3. CELEGENE CORPORATION

16.3.1. Company Details

16.3.2. Company Overview

16.3.3. Product Offerings

16.3.4. Key Developments

16.3.5. Financial Analysis

16.3.6. SWOT Analysis

16.3.7. Business Strategies

16.4. Eli Lily and Company

16.4.1. Company Details

16.4.2. Company Overview

16.4.3. Product Offerings

16.4.4. Key Developments

16.4.5. Financial Analysis

16.4.6. SWOT Analysis

16.4.7. Business Strategies

16.5. F. Hoffmann-La Roche Ltd

16.5.1. Company Details

16.5.2. Company Overview

16.5.3. Product Offerings

16.5.4. Key Developments

16.5.5. Financial Analysis

16.5.6. SWOT Analysis

16.5.7. Business Strategies

16.6. Johnson & Johnson Services, Inc.

16.6.1. Company Details

16.6.2. Company Overview

16.6.3. Product Offerings

16.6.4. Key Developments

16.6.5. Financial Analysis

16.6.6. SWOT Analysis

16.6.7. Business Strategies

16.7. Merck & Co., Inc.

16.7.1. Company Details

16.7.2. Company Overview

16.7.3. Product Offerings

16.7.4. Key Developments

16.7.5. Financial Analysis

16.7.6. SWOT Analysis

16.7.7. Business Strategies

16.8. Novartis AG

16.8.1. Company Details

16.8.2. Company Overview

16.8.3. Product Offerings

16.8.4. Key Developments

16.8.5. Financial Analysis

16.8.6. SWOT Analysis

16.8.7. Business Strategies

16.9. Pfizer Inc.

16.9.1. Company Details

16.9.2. Company Overview

16.9.3. Product Offerings

16.9.4. Key Developments

16.9.5. Financial Analysis

16.9.6. SWOT Analysis

16.9.7. Business Strategies

16.10. Polaris Pharmaceuticals

16.10.1. Company Details

16.10.2. Company Overview

16.10.3. Product Offerings

16.10.4. Key Developments

16.10.5. Financial Analysis

16.10.6. SWOT Analysis

16.10.7. Business Strategies

16.11. Other Market Participants

17. Key Findings

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

**Exclusive for Multi-User and Enterprise User.

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 163

    Backtrace:

    File: /var/www/html/ami/application/views/pages/reportpage.php
    Line: 163
    Function: _error_handler

    File: /var/www/html/ami/application/controllers/Report.php
    Line: 153
    Function: view

    File: /var/www/html/ami/index.php
    Line: 315
    Function: require_once